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Abstract
Drug-eluting stents have emerged as the most effective method for treating restenosis
following percutaneous coronary interventions. This thesis investigates how drugs with
similar physiochemical properties but different specific binding targets yield drastically
different tissue transport, retention and ultimately efficacy independent of their putative
biological effects. Our central hypothesis is that both specific and general binding of
drugs to tissue proteins, as mediated by drug-specific physiochemical properties, plays a
central role in arterial transport and distribution. We define and compare the kinetic and
transport properties of clinically implemented compounds with different binding modes.
While hydrophilic compounds are rapidly cleared, hydrophobic ones are retained with an
arterial transmural distribution dependent upon the distribution of specific and general
binding sites. Common systemically administered cardiac drugs compete with locally
delivered agents through displacement of general binding sites. Exploration of drug
binding in thrombus indicates significant specific and general binding capacity. Stent-to-
arterial wall drug transfer is acutely sensitive to stent strut position in clot relative to the
wall due to thrombus binding capacity. A poorly controlled microthrombotic
environment around a stent strut can drastically enhance systemic washout while
reducing delivery to the tissue. Together this body of work implies that specific and
general binding plays a critical role in the clinical efficacy of locally delivered drugs, and
must be a consideration in the rational design of stent-based delivery devices.
Thesis Supervisor: Elazer R. Edelman
Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology
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Chapter 1
Background and Significance
Overview of Thesis
Paclitaxel- and rapamycin-eluting stents have been overwhelmingly successful in
the treatment of atherosclerosis. These devices reduce the expected intervention-induced
tissue hyperplasia and clinical restenosis to an extent not seen with any other modality.
Yet, for each of these successes there have been multiple failures and a central question
has lingers: What distinguish the success of one drug over another in treating restenosis?
Heparin, dexamethasone and actinomycin-D all showed great promise in vitro and, all
failed in late stage clinical trials. One theory has been put forth that in vivo, compounds
like paclitaxel and rapamycin have unique biologic effects, different from those therapies
that prove ineffective. There is however little to no firm support for this possibility. In
contrast, our central hypothesis is that physicochemical, not pharmacological, properties
indeed can be used to distinguish drugs. In particular, we believe tissue retention to be a
critical factor for tissue effect. Drugs that are rapidly cleared can not reside long enough
to exert and effect. Compounds that bind to tissue elements can be in place for a
sufficient amount of time to influence tissue events. Specific and general binding to
target proteins allows certain drugs to remain in tissue and establish a meaningful
biologic effect. When a compound weakly binds to tissue elements, as may be the case
with unsuccessful treatments, it is too quickly cleared from the vessel before binding to
its biologically relevant protein to inhibit smooth muscle cell growth.
This thesis consists of a series of studies which attempt to elucidate the role of
specific and general binding in stent-based drug delivery. The specific aims are reflected
in the individual core chapters:
· Chapter 2 characterizes the arterial transport and distribution properties of model
hydrophilic and hydrophobic drugs with specific binding targets
· Chapter 3 defines specific and general binding in the context of local arterial drug
delivery.
8
* Chapter 4 characterizes the role of binding to thrombus and its effects on arterial
wall drug deposition
Through systematic study of physiochemical specific and general binding we
hope to elucidate one of the fundamental mechanisms that make stent delivery so
successful. Challenges remain in understanding how pathology changes the binding
domains of tissue, especially in disease states such as diabetes where restenosis rates are
significantly higher. The lessons of this work are generally applicable to fields of local
delivery beyond the cardiovasculature, and the implications are presented for a broad
audience.
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1.1 Death and Dying from Heart Disease
In 2002 over one million Americans died of heart disease, accounting for 100
million hospital days and nearly half of all deaths recorded in the United States. One-
third of the victims were under the age of 65. The American Heart Association estimates
that over 12 million Americans suffer from obstructive coronary artery disease,
principally from atherosclerosis. Ultimately, 90% of patients who die suddenly of heart
disease have significant coronary artery obstruction[ 1].
1.2 Normal Arterial Anatomy
Familiarization with the architecture of a normal artery is essential as we consider
effective treatments of coronary artery disease, stenting and arterial drug delivery.
Arteries are composite structures consisting of elastin, collagen, smooth muscle cells and
extracellular matrix arranged into three main layers, called tunics (figure 1). The tunica
intima is closest to the lumen and blood flow and is composed of a monolayer of
endothelial cells in animals and in humans vascular smooth muscle cells as well[2, 3].
Radial to, and supporting, the tunica intima lies the internal elastic lamina (IEL), a
fenestrated connective tissue layer composed primarily of hydrophobic elastin. The
tunica media, or middle layer, consists of concentrically arranged collagen and elastin
laminae. Packets of smooth muscle cells interpose these laminae and are oriented
orthogonally to the radial direction of the artery. The media is therefore ideally
constructed to modulate vascular tone, modulating vessel diameter and perfusion to
10
downstream tissues. The smooth muscle cells contract and relax under rhythmic
neurohormonal control and the laminae supply both cell support and elasticity. An
extracellular matrix composed of reticular fibers and chondroitin sulfate
glycosaminoglycans persists throughout the tunica media. Smaller muscular arteries
contain less organized elastic laminae, forming a network of fibers surrounding the layers
of smooth muscle cells[2, 3]. The external elastic lamina (EEL) separates the outermost
tunica adventitia from the tunica media as a series of concentric rings. The adventitia is
composed primarily of loose type I collagen and scattered fibroblasts, adipocytes and
nerve fibers. The adventitia of larger arteries (wall thickness greater than 500,m) is
permeated by a network of vasa vasorum, capillaries that help nourish the main vessel
wall[2].
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Fi2ure 1.1: Normal Arterial Anatomv
verHoeffs stain of an internal carotid artery wall [4]. In this
preparation, elastin is stained black, collagen is stained dark
pink, and cellular material is stained yellow. "I" represents
the intima.
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1.3 Atherosclerosis Pathogenesis
Atherosclerosis is thought to involve a complex series of events that begins with
endothelial injury and culminates in vascular obstruction. Thrombosis, inflammation,
smooth muscle cell phenotypic transformation, migration and proliferation are
accompanied by vascular remodeling[5-7]. Chronic hypercholesterolemia, diabetes,
systemic hypertension, or even exogenous etiologies like chemicals in cigarette smoke
have been associated with atherosclerosis. The evolving process begins with endothelial
dysfunction or "injury" and continues to develop over a number of years. Over time the
atherosclerotic lesion forms a thickened neointima on the luminal side of the internal
elastic laminae as lipids accumulate in macrophages and smooth muscle cells within the
new layer transforming these cells to foam cells. The accumulation of cells and
extracellular matrix forms the atherosclerotic plaque. Death of the foam cells produces a
necrotic environment rich in cholesterol esters lipids and potent cytokines which further
prolong the chronic inflammatory reaction. Neointimal inflammation and proliferation
can persist for years to decades culminating in the formation of a complex lesion,
characterized by a severely narrowed and often asymmetric lumen with a fibrous tissue
cap and a necrotic lipid core[7] (figure 2). These lesions are effectively scars from the
healing process of the initial endothelial injury and can remain stable and asymptomatic
for years. The neointima becomes vascularized over time where blood vessels, likely
from the vasa vasorum in the adventitia, permeate the atherosclerotic core nourishing and
promoting plaque progression. Myocardial infarctions, especially in the young, are often
associated with plaque rupture and the acute and occlusive thrombotic response that
13
follows, rather than progressive luminal occlusion due to plaque formation that occurs
with chronic disease in the older population.
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Fi2ure 1.2: Complex Atherosclerotic Lesion
Complex atherosclerotic lesion showing the lumen (L), the
neointima (N), fibrous tissue (F), a necrotic lipid core (LC),
evidence for a previous thrombus (T) and mural dissection
(D) [8].
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1.4 Mechanical Interventions and Restenosis
Angioplasty, atherectomy and endovascular stenting prevail as the most frequent
percutaneous coronary intervention therapies for symptomatic coronary atherosclerosis.
Prior to the introduction of drug-eluting stents nearly all mechanical interventions
designed to limit atherosclerotic disease inflicted significant damage to the very tissues
they were intended to help, resulting in a renewed and accelerated occlusive
vasculopathy[9-13]. In fact, these therapies accelerated the period of time to develop
clinically significant occlusive vascular disease from decades to months[12, 13] (Figure
3). 30-40% of patients receiving balloon angioplasty treatment become obstructed in six
months completely reversing the benefits of the initial intervention. This therapy-induced
pathology, known as restenosis, is defined as a progressive re-narrowing of the blood
vessel in response to the injury inflicted during the intervention.
Restenosis begins at the time of intervention as small tears develop in the arterial
wall. An inflammatory cascade ensues as a natural wound healing response. Platelets
and white blood cells from the blood adhere to the injured intima delivering power
cytokines which signal smooth muscle cells to migrate and divide in an attempt to repair
the injury. A new- or neointima of dividing smooth muscle cells forms, impeding blood
flow through the lumen. Despite similar mechanisms of pathogenesis the initial acute
insult of the restenotic lesions offer a separate and distinct disease from atherosclerosis.
In atherosclerosis, initial endothelial insult may be non-denuding and subtle. While
atherosclerotic lesions exhibit a protracted course, restenosis emerges in a period of
16
weeks to months. The restenotic neointima is primarily composed of smooth muscles
cells while the atherosclerotic lesion is complex with high densities of macrophages and
lipid deposits and, in advanced disease, calcification. Finally, the neointima of restenosis
exhibits a dynamic advancing front that is usually more uniform and concentric, and
completely envelopes the foreign body stent struts.
Ballon angioplasty- and endovascular stent-induced restenosis maintain different
pathologic courses. In balloon-injured arteries, leukocyte recruitment is generally
confined to early neutrophil infiltration with undetectable levels of pro-inflammatory
cytokines such as IL-8 and MCP-1 after injury. In contrast, stented arteries also exhibit
early neutrophil recruitment, but prolonged macrophage accumulation follows. Cytokine
mRNA and protein levels can still remain detectable for at least several weeks post
injury. The continued presence of macrophage maintains inflammatory cytokines levels
in the vicinity of the foreign body stent struts prolonging the wound response including
neutrophil recruitment with tissue remodeling[ 14].
17
Fieure 1.3: In-stent Restenosis
In-stent restenosis of a rabbit iliac artery 28 days post-
intervention [4]. The black stent struts are clearly visible
between the media (M) and the thick neointimal (N).
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1.5 Previous Attempts at Treating Restenosis
Despite the extended inflammatory response, bare metal intracoronary stents
significantly reduced the rate of restenosis compared to percutaneous balloon angioplasty
(PTCA) alone. PTCA is now used in fewer than 10% of de novo procedures and only
when stenting is not possible. Before the introduction of drug-eluting stents, two
landmark studies established bare metal stenting as the preeminent first-line therapy for
large vessel (3 mm or greater) coronary artery disease. The STRESS [15] (Stent
Restenosis Study, United States multicenter) and BENESTENT [16] (Belgium and
Netherlands Stent) trials randomly assigned patients to standard balloon PTCA or PTCA
with elective stent placement. Both trials reported a significant reduction in angiographic
restenosis (22 versus 32%) and decreased the need for repeat revascularization at six or
seven month follow-up (17 versus 25%). Routine stenting unequivocally improves the
in-hospital outcome when compared to PTCA alone. Stenting reduced the in-hospital
mortality (0.3 versus 0.6% for PTCA) and the need for emergent coronary artery bypass
grafting (CABG) (0.3 versus 0.7%) [17]. A retrospective review of 1240 stented patients
and 4018 patients who underwent PTCA found that the risk of in-hospital CABG or death
was reduced with stenting (3.1 versus 5.3 for no stent, adjusted odds ratio 0.63). The risk
reduction was primarily associated with a 52% decrease in need for CABG or follow-up
revascularization procedure (12.5 versus 17.6%, adjusted odds ratio 0.72) [18]. Stenting
however had no effect on the six month incidence of MI or cardiac death[ 19].
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Increasingly sophisticated techniques have not reduced restenosis rates relative to
bare metal stents, and in some cases even performed more poorly. With excimer laser
angioplasty, 50% of patients experienced angiographic evidence of restenosis at six
months[20, 21]. Atherectomy devices show similar results[22, 23]. Bypass grafting
yields a tenuous post-operative course with a seven year mean lifetime for a saphenous
vein aorto-coronary interposition graft. 10% of grafts become occluded within the first
two weeks after surgery, 20% within a year and 35% within five years[13, 24].
Fortunately, shared immunologic, metabolic and proliferative stimuli have been
identified in all these settings, paving the way for the administration of vasoactive agents
to combat restenosis.
Early advances in vascular biology suggested that potent vasoactive compounds
might selectively target specific cellular events involved in the pathogenesis of restenosis.
Numerous candidate drugs were tested with systemic administration in animal models
including, heparin[25-36], anti-inflammatory drugs such as dexamethasone[37, 38],
antimitotic inhibitors of tubulin polymerization or depolymerization such as
colchicine[39] and paclitaxel[39-43], anti-platelet drugs such as forskolin[44, 45],
antineoplastic agents such as actinomycin-D[46, 47] and antisense oligonucleotides
directed against cell cycle proteins such as c-myc[48]. Many of these agents offered
early promising results, but at therapeutic doses caused inadvertent injury to other tissues
with rapidly dividing cells, including the gut epithelium, hair follicles and lymphoid cells.
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With rapid drug degradation and denaturation for many of these compounds, profoundly
toxic drug doses would be required to treat restenotic events.
1.6 Birth of Local Delivery
Local delivery offered a viable alternative to systemic methods, allowing for
pharmacologic, nontoxic and targeted delivery. Heparin-eluting polymeric perivascular
wraps in rats offered the first evidence of successful local delivery, out performing
continuous pump infusion[49]. Pressurized drug infusion catheters were soon developed
for high local dosing during interventions but unfortunately the candidate drugs including
heparin and methotrexate showed little benefit in restenosis treatment[28, 50-52].
Additionally, upon removing the catheter, systemic drug wash out had adverse effects on
non-target tissues.
Controlled-release devices allow for high and sustained levels of antiproliferative
drugs over a period of days to weeks[53-55]. Controlled-release polymers have been
engineered into endoluminal sheaths[56], perivascular wraps and beads[29, 57, 58] for
sustained local delivery of antiproliferative agents designed to inhibit the
pathophysiologic processes that lead to intimal hyperplasia and restenosis. Incorporating
a polymeric coat directly onto an endovascular stent scaffolding has rapidly become the
industry standard for treating restenosis[53, 54, 59] (Figure 4).
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Despite demonstrated efficacy in tissue culture and animal models, early attempts
at administration of forskolin, dexamethasone and actinomycin-D from stent platforms
failed to decrease rates of clinical restenosis[38, 44, 45, 50, 59-61]. Paclitaxel and
rapampycin, on the other hand, are now the most efficacious methods available for
treating restenosis.
22
Fhmre 1.4: Druf!-coated Stent
Pac1itaxel-coated NIR stent (Medinol) in the collapsed state
on the delivery catheter (above) and in the inflated state
(below).
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1.7 Drug-eluting Stent Trials
Numerous trials have been conducted comparing paclitaxel-eluting stents to bare
metal stents, rapamycin-eluting stents to bare metal stents as well as head-to-head
evaluations of paclitaxel and rapamycin stents performance. The TAXUS II trial enrolled
536 patients with low risk lesions, randomly assigning bare metal or paclitaxel-eluting
stent treatments[62]. At six months, the paclitaxel stent showed significant reductions in
both in-stent restenosis (3.5 versus 19.1%) and target lesion revascularization (3.9 versus
13.3%). Benefits of the paclitaxel stent were confirmed in the larger TAXUS IV trial
where 1314 patients with previously untreated coronary stenoses were assigned
paclitaxel-eluting or bare metal stents[63].
The RAVEL trial enrolled 238 patients for evaluation of the rapamycin-eluting
stent versus the bare metal stent[64, 65]. At six months, with the metric of restenosis of
more than 50% of the luminal diameter, rapamycin far outperformed the bare metal stent
(zero versus 27%). The larger SIRIUS trial of 1058 patients evaluated overall
performance and subcategorized patients with complex disease including long lesions
(mean 14.4 mm), small target vessels (mean 2.8 mm), and patients with diabetes
(26%)[66]. Clinical and angiographic follow-up at nine months demonstrated a
significant benefit of rapamycin stents over bare metal stents for angiographic in-stent
restenosis (3 versus 35%) and target lesion revascularization (4 versus 17%). These
benefits were consistent across the subgroups, including longer lesions, smaller vessels
and diabetic patients[67].
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While paclitaxel and rapamycin stents certainly out perform bare metal stents and
balloon angioplasty, emerging reports indicate significant clinical performance
divergences between the two drug-eluting therapies. Several randomized trials have
directly compared the rapamycin and paclitaxel stents. The TAXi trial randomly
assigned 202 patients with de novo lesions to a rapamycin or paclitaxel stent[68]. Mean
follow-up at seven months demonstrated statistically insignificant difference in rates of
target vessel revascularization necessity (3 versus 1% for paclitaxel). Both stents also
show similar rates of thrombotic occlusion at 1%[69]. More recently, the ISAR-Desire
trial confirmed no statistical difference between restenosis rates in rapamycin- and
paclitaxel-eluting stents after revascularizing for in-stent restenosis (14% vs. 22%,
respectively, p = 0.19)[70]. However, the incidence of target vessel revascularization
was significantly different for in-stent restenosis patients (8% for rapamycin and 19% for
paclitaxel, p = 0.02). The most distinctive advantage of drug-eluting stents is the reduced
need for target vessel revascularization. This clinically relevant performance metric
highlights the need for further exploration of the functional characteristics of the various
drug-eluting stent formulations.
1.8 Challenes in Treatment of Restenosis
When restenosis does occur with drug-coated stents, the poor performance has
been attributed to a number of possible factors including extensive local vessel injury
during the procedure, gaps in stent coverage or inadequate stent expansion[71, 72] and
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even lesion complexity. The RESEARCH study of 238 patients found that in-segment
restenosis occurred in 7.9% at six months. Several factors were identified as multivariate
predictors of restenosis: treatment of in-stent restenosis (restenosis rate 19.6%), ostial
lesion location (14.7), diabetes mellitus (14.3%), stented length >26 mm (13.9%),
reference vessel diameter <2.17 mm (10.3%), vessel other than left anterior descending
coronary artery (10.8%)[67]. Distinct performance characteristics of one eluted
compound over another may tailor therapeutic choices for higher risk conditions.
Central to our understanding of drug-eluting stent therapy efficacy is the
hypothesis that local drug concentration variations, even on the length scale of single
cells, can affect the macroscopic outcome with regards to efficacy[73, 74]. Work by
Lovich and Creel et al. showed that a hydrophobic drug like paclitaxel distributes
inhomogenously across the arterial wall. Extensive work by Hwang et al. has shown that
variability in clinical results might be explained by local drug distributions and the
influence of local transport forces, local tissue structure and drug-tissue interactions
("local pharmacokinetics"). Their work showed that arterial wall uptake for hydrophilic
drugs such as dextrans depend on vessel elastin content, such that arteries with greater
elastin content have a higher partition coefficient than arteries with greater cellular
content. They also found that geometric organization of the elastic laminae also causes
significant anisotropy in transport where diffusivity in the planar direction exceeds that in
the transmural direction by over an order of magnitude for hydrophilic drugs and for
hydrophobic drugs which interact with serum carrier proteins like albumin.
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This microscopic view of pharmacokinetics in addition to the traditional one is
vital to understanding drug-eluting stent therapies. Unfortunately, tremendous drug
concentration gradients are invariably established by transport forces such that drug
concentrations in adjacent cells can differ significantly[75]. Local tissue ultrastructure,
and the concentrations they enforce on the artery at a microscopic scale, become
important considerations in the optimization of vascular drug delivery.
1.9 Definitions of Binding
Building on the fundamental tenets of local pharmacokinetics, this work will
explore the roles of specific and general binding in local arterial drug delivery. Specific
binding is defined as the association of a particular drug with its biologically relevant
binding protein. Paclitaxel specifically binds to polymerized microtubules to inhibit
tubulin depolymerization during cell DNA replication, prevent mitosis. Rapamycin
specifically complexes with the FK506 binding protein (FKBP) and the mammalian
target of rapamycin protein (mTOR). This heterotrimer prevents nuclear translocation of
cell cycle critical protein, thereby inhibiting replication. General binding is defined as
the association of drug with all tissue elements other than the therapeutically relevant
binding protein.
27
1.10 Thesis Theme
With the overwhelming success of paclitaxel and rapamycin in the stent-based
treatment of' restenosis, a central question lingers: What physiochemical parameters
distinguish the success of one drug over another? Where heparin, dexamethasone and
actinomycin-D all showed early promise at inhibiting smooth muscle growth in culture
and intimal hyperplasia in controlled animal trials, all failed in late stage clinical trials.
One theory has been put forth that in vivo, compounds like paclitaxel and rapamycin have
unique biologic effects, different from those therapies that prove ineffective. There is
however little to no firm support for this possibility. In contrast, our central hypothesis is
that physicochemical, not pharmacological, properties can be used to distinguish drugs.
In particular, we believe tissue retention to be a critical factor for tissue effect. Drugs that
are rapidly cleared can not reside long enough to exert and effect. Compounds that bind
to tissue elements can be in place for sufficient time to influence tissue events. Specific
and general binding to target proteins allows certain drugs to remain in tissue and
establish a meaningful biologic effect. When a compound weakly binds to tissue
elements, as may be the case with unsuccessful treatments, it is quickly cleared from the
vessel and cannot inhibit growth. Challenges remain in understanding how pathology
changes the binding domains of tissue, especially in disease states such as diabetes where
restenosis rates are significantly higher. In other fields of local delivery, the lessons of
this work are generally applicable and the implications are presented for a broad
audience.
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1.11 Thesis Organization
This thesis consists of a series of studies which attempt to elucidate the role of
specific and general binding in stent-based drug delivery. The specific aims are:
· Chapter 2 characterizes the arterial transport and distribution properties of model
hydrophilic and hydrophobic drugs with specific binding targets
* Chapter 3 defines specific and general binding in the context of local arterial drug
delivery.
* Chapter 4 characterized the role of binding to thrombus and its effects on arterial
wall drug deposition
Through systematic study of physiochemical specific and general binding we
hope to elucidate one of the fundamental mechanisms that make stent delivery so
successful.
29
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Chapter 2
Specific Binding in Arterial Tissue
Abstract
Endovascular stents eluting drugs have changed the practice of medicine and yet
it is unclear how they achieve such effect and how to distinguish between the different
formulations available. Biological drug potency is not the sole determinant of biological
effect, physicochemical drug properties dominate as well. Hydrophobic drugs are
retained within tissue and have dramatic effects while hydrophilic drugs are rapidly
cleared and ineffective against restenosis. The question arises as to whether individual
properties of different drugs beyond lipid avidity can further distinguish arterial transport
and distribution. In bovine internal carotid arterial segments, tissue loading profiles for
hydrophobic paclitaxel and rapamycin are indistinguishable, reaching load steady-state
after 2 days. Hydrophilic dextran reaches equilibrium in several hours at levels no higher
than surrounding solution concentrations. Both paclitaxel and rapamycin bind to the
artery at 30-40 times bulk concentration. Competitive binding assays confirm binding to
specific tissue elements. Most importantly, the transmural drug distribution profiles are
markedly different for the two compounds, reflecting perhaps different modes of binding.
Rapamycin, which binds specifically to the FKBP12 binding protein, distributes evenly
through the artery while paclitaxel, which binds specifically to microtubules, remains
primarily in the sub-intimal space. The data demonstrate that specific binding of
rapamycin and paclitaxel to fixed tissue proteins plays an essential role in determining
arterial transport and distribution and in distinguishing one compound from another.
These results offer further insight into the mechanism of local drug delivery and the
specific use of existing drug-eluting stent formulations.
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2.1 Introduction
It now appears that the success of drug-eluting stents is predicated to as great a
degree upon the extent of drug deposition and distribution through the arterial wall as
virtually any other factor(1-5). The biological effects of a candidate drug are essential,
but ultimately tissue residence time will determine effect and toxicity(6, 7). Fueled by its
clinical relevance(8-1 1) a number of studies have been carried out to detect, model and
predict the distribution of drugs within arterial segments beneath, adjacent to and a
distance from stents(12-15). Drugs that are retained within the blood vessel are far more
effective than those that are not. Heparin, is a perfect example of a compound whose
ubiquitous biological potential is lost by virtue of its physicochemical properties.
Heparin regulates virtually every aspect of the vascular response to injury(16). Yet
heparin is so soluble and diffusible that it simply cannot stay in the artery for more than
minutes after release and has no effect on intimal hyperplasia when eluted from a stent(4,
17, 18).
Paclitaxel in contradistinction is a far smaller compound with fewer effects
specific to vascular biology, but paclitaxel is so hydrophobic and insoluble that it binds
tenaciously to tissue protein elements and remains beneath stent struts long after
release(13). The clinical efficacy of paclitaxel at reducing restenosis rates following
elution from stents appears incontrovertible(8, 11). In addition to its hydrophobic general
binding behavior, paclitaxel also binds to its protein target, polymerized
microtubules(19), with nanomolar specificity. Analogously, rapamycin, also successful
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after local vascular delivery(10), acts on a specific target through a series of events that
requires binding to the specific binding proteins FKBP12 (FK506 binding protein 12) and
FRAP (FKBP12-Rapamycin Associated Protein)(20, 21). Thus, we hypothesized that the
tissue specific binding proteins can significantly influence arterial wall drug distribution
and local pharmacological effects for compounds like paclitaxel and rapamycin above
and beyond the influence of hydrophobic general interactions alone. The distribution of
tissue binding proteins is not uniform in space or in time. For example, FKBP12 is found
most abundantly in vascular smooth muscle cells at a concentration of 10-5M(22).
FKBP12 is upregulated with injury in neuronal systems(23) and likely after arterial injury
as well. Microtubules have a similar cellular concentration of -10 5M(24). The non-
uniform distribution of paclitaxel previously observed in the arterial wall may reflect an
inhomogeneous distribution(13) of polymerized microtubules or carrier proteins(25).
While regulated at a coarse level by transport forces and lipid avidity, the distribution of
paclitaxel and rapamycin is also regulated at a fine level by the distribution and
availability of their protein targets, a level of control not present for drugs like heparin
that do not specifically bind to arterial wall proteins. With a more complete
understanding of the role of specific binding in arterial drug distribution, stent design,
drug composition and release formulation can be better optimized.
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2.2 Methods
Arterial Loading and Elution
We defined the tissue pharmacokinetic profiles of dextran (10,000 Da), paclitaxel
(853.9 Da), and rapamycin (914.2Da) in calf carotid arterial wall segments. Calf internal
carotid arteries were harvested and transported in phosphate buffered saline with
physiological calcium and magnesium added (PBS ++, 0.01 mol/L CaC12 and 0.01 mol/L
MgCl2, Sigma) at 40 C. Arteries were cleaned of excess fascia, opened longitudinally, cut
into segments (400 to 600 mg), and placed in centrifuge tubes with 1.0 mL of
[3H]dextran, [3 H]paclitaxel or [14C]rapamycin. All bulk solutions were made fresh
immediately before experimentation.
For loading experiments, segments were removed in triplicate at indicated time
points, briefly washed in PBS++ and blot-dried before being dissolved in Solvable
(Packard-Canberra). Liquid scintillation cocktail (6 ml) was added to dissolved samples
before counting with liquid scintillation spectroscopy (2500 TR Liquid Scintillation
Analyzer, Packard-Canberra). For elution experiments, segments were allowed to
equilibrate for 48 hours and were then placed in 50ml of PBS++ for the indicated time
periods before being processed in triplicate as indicated with the loading experiments.
Measurements of Transmural and Planar Diffusion
Planar and transmural diffusivities were measured using diffusion cells. Planar
diffusivities (diffusion in the plane of the elastin sheaths) were measured by mounting
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opened arterial specimen between two glass slides and contacting the specimen's edge to
a drug bath. After 25 minutes (a time determined to provide adequate diffusion and
signal to noise ratio) specimens were processed for liquid scintillation counting. Planar
diffusivities were measured in the longitudinal and circumferential direction. For
transmural diffusivity, cleaned arteries were opened longitudinally and clamped in a
standard Franz diffusion cell consisting of an upper sink compartment containing PBS++,
separated from a drug-containing lower compartment by an artery lying en face. The
artery was thus exposed only to drug on the luminal side and only to buffer on the other.
After 25 minutes of exposure to the drug, samples were processed for liquid scintillation
counting.
The arterial wall is a highly heterogeneous structure composed of different tissue
layers which impose individual effective diffusivities. Yet, there is a regularity from the
alternating cylindrical bands of connective tissue and smooth muscle cells that permits
use of a lumped effective diffusivity parameter to characterize bulk drug transport
properties in the arterial wall(13). Lumped effective diffusivities can be calculated from
the measured drug mass M in tissue, using the early time solution to the diffusion
equation:
D r
t 2.A.C.k
where t is the time, A is the artery area exposed to drug, k is the binding capacity
coefficient, C is the drug source concentration(3).
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Drug-Tissue Binding Capacity and Distribution
We defined the bulk differential capacities of the arterial wall for dextran,
paclitaxel and rapamycin at equilibrium. Arterial segments were weighed before being
placed in drug bath solutions. Segments were allowed to equilibrate for 48 hours and
were then processed for liquid scintillation counting. The drug concentration of each
tissue sample was normalized by tissue mass and then by drug concentration in the bulk
fluid during equilibrium incubation to determine the binding capacity.
Equilibrated transmural arterial drug distribution was measured through en face
cryosectioning. Arterial segments were incubated in drug bath for 60 hours, then laid flat
and snap frozen in a plastic encasement with OCT Embedding Medium (Tissue-Tek,
Sakura Finetechnical Inc). Samples were stored in a -800 C freezer until sectioning
parallel to the intima with a refrigerated microtome (Cryotome SME, Shandon, Inc.)(12,
26, 27). Upon sectioning, the segment length and width were measured with a caliper.
0.020-mm thick sections were cut parallel to the intima and the drug content of each
sample was determined by liquid scintillation spectroscopy. Tissue drug concentration
(cr) at each transmural location was calculated as the mass of drug normalized by the
measured tissue area and slice thickness. Tissue drug concentration was then normalized
by the bulk fluid drug concentration during equilibrium incubation (Cbulk) to determine the
binding capacity (k) at each transmural location x:
k(x) = cT(x)/cbulk
40
2.3 Results
Tissue Loading Kinetics
Arterial samples were incubated in [3 H]dextran, [3H]paclitaxel or [14C]rapamycin
and harvested in triplicate over a period of 72 hours. As the drugs span a range of
specific activities preventing use of equivalent initial bulk concentrations, loading data
was normalized to an average peak value at 72 hours (Figure 2.1). While the hydrophilic
dextran reached 80% of equilibrium value with in several hours, paclitaxel and
rapamycin took nearly 24 hours to achieve the same level. The loading profiles for these
two hydrophobic compounds are indistinguishable and approach steady state only after
48 hours.
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Figure 2.1: Tissue Loading
Pharmacokinetic tissue loading profile of radioactive dextran (),
paclitaxel () and rapamycin (0) in bovine internal carotid tissue
segments.
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Tissue Elution Kinetics
Arterial samples were pre-equilibrated in [3H]dextran, [3H]paclitaxel or
[14C]rapamycin for 60 hours and then placed in an elution sink of 50ml of PBS++.
Samples were processed in triplicate over the following 48 hours and data plotted as
percentage of the pre-elution load value (Figure 2.2). Dextran elutes most rapidly, losing
90% of its equilibrated load within 2 hours and reaching a steady-state of -10% of
original material in less than 5 hours. The hydrophobic drugs take -24 hours to reach an
elution steady-state value. At 48 hours arterial segments loaded with rapamycin retain
-60% of their initial load, and paclitaxel 35%.
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Bulk Diffusion Measurements
Effective planar and transmural diffusivities in the carotid artery were measured
directly from the mass of drug transferred into the arterial wall (n=3) using the early-time
solution of the diffusion equation(3) (Figure 2.3). Diffusivities in the circumferential and
longitudinal direction were equivalent (data not shown). Planar coefficients represent
measurements in the longitudinal direction. All compounds demonstrated anisotropic
diffusivities, with more rapid planar than transmural diffusivity. Dextran diffusivity was
two orders of magnitude greater than either of the hydrophobic compounds in both planar
and transmural directions despite their 20-fold smaller size than the dextran. Anisotropic
diffusion varies with molecular mass, invalidating the assumption that drug-tissue
diffusion problems can assume a simple molecular conformation in a homogenous media.
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Figure 2.3: Arterial Wall Diffusion Coefficients
Planar () and transmural () diffusion coefficient of radioactive dextran,
paclitaxel and rapamycin in bovine internal carotid tissue segments.
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Tissue Binding Capacity (TBC) Coefficients
Tissue binding capacity (TBC) was defined as the tissue concentration (CT) at
equilibrium normalized by the bulk concentration at equilibrium (CBulk). Arterial
segments were incubated in drug for 60 hours to allow for equilibration. Upon
equilibration, bulk solutions were sampled and tissue samples were processed for liquid
scintillation counting. Variation in initial bulk concentrations over an order of magnitude
did not affect TBC. Dextran has no binding capacity in arterial tissue with a coefficient
of -0.60 (data not shown). As this value is similar to its physically accessible volume
fraction of arterial tissue(17) dextran may not leave the extracellular space. Paclitaxel
and rapamycin have binding coefficients greater than 1 indicating that general and/or
specific binding interactions are sequestering these drugs in the tissue (Figures 2.4 and
2.5).
To assay for the binding specificity, experiments were conducted with mixtures of
hot and cold drug. At a stock solution of 10-8 M paclitaxel TBC was 42 (Figure 2.4). As
the amount of non-labeled drug was introduced in a solution of radiolabeled paclitaxel
the TBC dropped as well indicating that paclitaxel binding sites were saturated by cold
drug, excluding the hot. As a negative control, 10-8M radiolabled paclitaxel was mixed
with a 1000-fold molar excess of non-labeled rapamycin, which does not bind
specifically to polymerized tubulin and the TBC decreased to 22 (data not shown)
indicating that only half of the paclitaxel TBC was due to general binding, as rapamycin
displaced paclitaxel involved in general protein interactions. A similar experiment was
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conducted with radioactive rapamycin (Figure 2.5). However, because of differences in
specific activity, we employed a labeled-rapamycin stock solution of 10-5M, at nearly the
level of FKBP saturation. At a 1:1 labeled to unlabeled rapamycin ratio the TBC dropped
to 17, just above half of the control value of 30. When the supersaturated non-radiolabel
rapamycin was in 100 fold excess the TBC dropped to 4. As a negative control hot
rapamycin was mixed with a molar excess of cold paclitaxel and the TBC moved to 13
(data not shown), nearly half of the control value. These data suggest as well that slightly
less than half of the rapamycin TBC is from general binding effects.
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Figure 2.4: Tissue Binding Capacity
Tissue binding capacity of labeled dextran, rapamycin and paclitaxel in
internal carotid tissue segments after 60 hours of equilibration.
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Fieure 2.5: Specific Binding Capacity
Fractional tissue binding capacity of labeled paclitaxel () and labeled
rapamycin () relative to pure labeled drug in internal carotid tissue segments
after 60 hours of equilibration for the following conditions: (1) Rx, 10-6M
labeled drug plus 10-3M of the same unlabeled drug. (2) Rx', 10-6M labeled
paclitaxel plus 10-3M unlabeled rapamycin and 10-6M labeled rapamycin plus
10-3M unlabeled paclitaxel.
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Transmural Drug Distribution
Arterial samples were incubated in [3H]dextran, [3H]paclitaxel or [14C]rapamycin
for 60 hours and then snap frozen for en face sectioning (Figure 2.6). Previous work with
paclitaxel showed that TBC was maximal in the intima and declined precipitously within
the most intimal regions of the arterial media to less than half the intimal level. At the
outer edge of the media, the paclitaxel binding capacity increased gradually and peaked
within the adventitia before falling off to near unity(13). These data have been
recapitulated from Creel et al for comparison with dextran and rapamycin. Dextran again
shows little binding capacity throughout the artery. Rapamycin shows a uniform
transmural distribution, in stark contrast to the non-uniform distribution of paclitaxel. It
is important to note the data from Creel et al. was conducted with paclitaxel
concentrations near the polymerized tubulin saturation limit. When paclitaxel
distribution experiments were repeated at lower sub-saturation concentrations, the TBC
was higher though with a similarly heterogeneous transmural distribution (data not
shown).
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Fi2ure 2.6: Transmural Equilibrium Drug Distributions
Transmural equilibrium distribution of labeled dextran (+), paclitaxel () and
rapamycin (0) in 0.040mm thick bovine internal carotid tissue segments.
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2.4 Discussion
Local drug delivery has great theoretical and practical appeal for vascular
disease(28, 29). One important surprise is that biological potency is not the sole
determinant of biological effect. Drug-specific physiochemical properties determine to a
great degree whether concentrations sufficient for therapeutic activity can be sustained.
Hydrophobic drugs, for example, are retained within tissue and have dramatic clinical
effects; hydrophilic drugs are rapidly cleared and ineffective against restenosis. The data
now suggest that specific binding also plays a critical role in determining drug
distribution. While Creel et al.(13) showed that paclitaxel distributed heterogeneously
through arterial tissue, our present data demonstrate that rapamycin distributes more
uniformly through the media and adventitia. In addition, the tissue binding and diffusion
results suggest that binding site availability and distribution regulate the fine structure of
drug deposition beyond the coarse structure imposed by transport forces and lipid avidity.
Ultimately, local tissue ultrastructure and the concentrations they enforce on the artery at
a microscopic scale together with specific and general binding site distribution become
critical considerations in the optimization of vascular drug delivery.
Specific and General Binding Determine Tissue Binding Capacity
Hydrophobic compounds must bind to proteins, fixed and soluble, to have a
biological effect. This binding can take two forms; general interactions such as charge or
water affinity, and specific binding idiosyncratic to the individual drug. Paclitaxel and
rapamycin can both bind generally to serum proteins and hydrophobic tissue micro-
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environments. Paclitaxel demonstrates nanomolar specificity to polymerized
microtubules while rapamycin shows similar specific binding properties to FKBP12, a
ryanodine receptor associated protein. Dextran, by virtue of its extreme hydrophilicity
exhibited neither type of binding and accordingly its TBC was less than one, and its
potential tissue level can never exceed what the concentration in bathing solution. In
contrast, paclitaxel and rapamycin were deposited in the blood vessel at concentrations
30-40 fold higher than in surrounding bulk solution. Thus, tissue concentrations of
hydrophobic paclitaxel and rapamycin can exceed the applied concentration several-fold
establishing an effective volume of distribution within arteries larger than anticipated
from surrounding solution concentration.
The specificity and potential of tissue binding was demonstrated by serial dilution
experiments. The TBC for radiolabeled paclitaxel remained substantially greater than
one until the non-radiolabeled drug was in 100-fold excess of the 10-8M bulk solution and
only fell significantly at 1,000-fold excess. Intriguingly, microtubules bind paclitaxel and
reside in calf internal carotid segments at -10-5M(24) suggesting that microtubules
account for a specific binding of paclitaxel in our system. Some of the displacement is
general. When cold paclitaxel was substituted for a high concentration molar excess of
rapamycin the TBC dropped nearly in half. Similar results were obtained when the same
procedures were carried out with labeled rapamycin. As the specific activity of the
radiolabel dictates a working concentration of 10-5M, near the FKBP12 saturation limit,
rapamycin TBC dropped in half upon mixing an equal amount of cold rapamycin and hot
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rapamycin. As with paclitaxel when hot rapamycin was mixed with excess cold
paclitaxel, the TBC also dropped in half. Thus, tissue distribution of both drugs are
governed by almost equal parts of specific and general binding events.
Tissue Pharmacokinetics of Hydrophilic and Hydrophobic Compounds
It is expected that paclitaxel and rapamycin will have similar transport properties
given that both compounds have solubilities of -6ug/ml, molecular weights of less than 1
kD and nanomolar binding constants to their specific protein targets. Indeed, the
compounds act quite similar when compared to dextran. While the latter takes several
hours to reach a steady state tissue concentration lower than the surrounding media,
paclitaxel and rapamycin reach near identical levels but after far greater than 1 day.
Kinetics not concentration account for this effect as the time to reach steady state was
independent of the concentration applied over a broad range. While net binding was
identical distribution and tissue elution after binding and uptake were not. At steady state
the artery retained only 10% of the applied hydrophilic dextran. Paclitaxel retention was
3.5-fold higher, and rapamycin almost twice paclitaxel levels. With similar elution
kinetics, the paclitaxel-rapamycin disparity suggests that rapamycin has twice the number
of specific binding sites relative to paclitaxel. Moreover, while paclitaxel remained in the
subintimal space, rapamycin was evenly distributed throughout the arterial wall.
Movement of a molecule through a composite structure like a blood vessel wall is
driven by a range of forces and phenomena. The influence of effective molecular radius
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can dominate when all other factors are equal, but may recede in importance when other
factors are present. For instance, despite being nearly 20-fold smaller than dextran,
paclitaxel and rapamycin diffuse more slowly in both the transmural and planar
directions. This difference may be attributed to the hydrophobicity of the compounds or
possibly to the role of binding. While dextran has few binding sites, paclitaxel and
rapamycin will repeatedly bind to and dissociate from their respective specific and
general targets as they diffuse through tissue, in effect slowing the leading edge of the
diffusion front.
We have previously shown that albumin and dextrans diffuse at least an order of
magnitude faster in the planar than in the transmural direction(3). For paclitaxel and
rapamycin the planar diffusivity exceeded transmural diffusivity by at least two orders of
magnitude although for both drugs their respective diffusivities were two orders of
magnitude smaller than those of dextran. These phenomena are likely governed by
similar forces for all three drugs despite vastly different lipid avidities. The transport of
hydrophilic compounds is enhanced in aqueous regimes of the vessel wall, but retarded
by hydrophobic elastin layers. For hydrophobic compounds, these layers act in a reverse
fashion; the movement of paclitaxel and rapamycin is likely impeded by the more water-
rich regions of the blood vessel wall and aided by lipid pools or even the protein-studded
elastin lamina. In both cases however, while individual layers might be isotropic, the
greater composite of alternating layers of the arterial wall provide for planar diffusion
that far exceeds transmural flux.
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Conclusions
As the number of available drug-eluting devices increases, distinction and choice
may reside not only in ease of use but in the physicochemical functionality of the drug-
stent unit. Local drug distribution is modulated by transport and lipid avidity at a coarse
level, but for clinically relevant compounds like rapamycin and paclitaxel, also by the
distribution of their specific binding sites. Arterial ultrastructure also influences transport
as alternating tissue layers of varying permeability result in anisotropic transport for both
hydrophobic and hydrophilic drugs. Design and evaluation of a drug-eluting device thus
requires a unified understanding of the drug, its physicochemical characteristics and its
specific and general interactions with arterial structures.
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Chapter 3
Specific and General Binding Competition
Abstract
The efficacy of drug-eluting stents (DES) requires the delivery of potent
compounds directly to underlying arterial tissue. The commercially available DES drugs
rapamycin and paclitaxel interact with general protein elements in tissue as well as
specific target sites. The question arises then as to whether other locally released
compounds or systemically circulating drugs will alter tissue deposition to either of these
sites and consequently change overall effect. The ability of either DES drugs to compete
for specific protein binding and tissue deposition was assessed and compared to effects of
other commonly administered cardiac drugs. Paclitaxel and ramaycin do not affect the
other's binding to their biologically relevant specific protein targets, but can generally
displace each other from tissue at three log order molar excess, decreasing arterials loads
by greater than 50%. Specific and general binding sites for both drugs are distributed
across the media and adventitia with higher specific binding associated with the higher
specific binding site densities in the media. Drugs classically used to treat standard
cardiovascular diseases, such as hypertension and hypercoaguability, also generally
displace rapamycin and paclitaxel, possibly decreasing tissue reserve capacity for locally
delivered drugs. Local competitive binding should not limit the placement of rapamycin
and paclitaxel eluting stents in close proximity. Commonly administered systemic drugs
can however compete with locally delivered rapamycin or paclitaxel to decrease tissue
reserve capacity.
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3.1 Introduction
The viability of candidate drug-eluting stents has been linked to the properties of
the drugs they release. Successful devices elute compounds that penetrate and can be
retained in tissue at high local concentrations. Failed devices seem to have considered
drugs that are rapidly cleared from arterial tissue [1-4]. A hydrophilic compound like
heparin cannot be made to stay in tissue to exert its numerous vasoactive effects over
clinically viable time periods[5-7]. Rapamycin and paclitaxel have emerged as the two
leading clinical therapies for stent delivery in major part because aside from their putative
biological effects their physiochemical properties favor prolonged tissue retention.
Paclitaxel binds specifically to a heterodimer of tubulin and in a more general manner to
a range of plasma and tissue bound proteins. Rapamycin exhibits a similar effect as it
specifically associates with the FK506 binding protein complex (FKBP) and binds
generally to a wide range of nonspecific proteins. Neither rapamycin or paclitaxel are
large compounds. They are both less than 1000 Da. Yet, their insolubility and the
immediate impact of protein binding markedly reduces convection velocities compared to
much larger, but much more readily diffusible and soluble compounds, like heparin. The
confluence of these physical forces creates a relatively high overall partitioning within
arterial tissues. Though more similar to each other than to other hydrophilic drugs the
long term retention, elution from and distribution within arteries do differ significantly
for these two compounds. It has been hypothesized that this difference derives in part
from the dissimilar distribution in FKBP[8, 9] and polymerized microtubules [10].
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As local binding is critical to local effect two questions arise with the increasing
use of these devices. First, as the number of stents implanted per procedure and in a
given artery rises concern has been raised as to the potential interactions of the same or
different drugs eluted from multiple adjacent or over-lapping DES. Second, will the
powerful circulating medications patients receive potentially change the binding of drugs
eluted from the stents. In part these two questions pose the polar ends of a spectrum of
issues. In the first case the question is whether high local tissue levels of drugs that have
almost undetectable circulating concentration compete with each other when both are
directed to the same defined target tissue, and the second is whether high steady state
circulating levels of a systemically administered drug can compete with the tissue binding
of a locally eluted compound. Accordingly, we examined the general and specific tissue
binding of rapamycin and paclitaxel in the presence of added amounts of these
compounds or common systemically administered cardiac drugs.
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3.2 Methods
Tissue Binding Competition Assays
Rapamycin was generously donated by Johnson and Johnson/Cordis, radiolabeled
Paclitaxel was provided by Vitrax and unlabeled Paclitaxel was from LC Laboratories.
For all tissue experiments radiolabeled drugs were loaded at 10-6 M in 1cm2 fresh bovine
calf carotid artery tissue. Rapamycin blocked general binding sites for paclitaxel tissue
uptake, and -vice versa, with each molecule serving as a competitive antagonists for the
other's general binding sites. Specific binding was inhibited with FK506 (Eton
Bioscience) and colchicine (Sigma). FK506 displaces rapamycin as it binds to the same
site on the FKBP protein, and colchicine displaces paclitaxel binding by stabilizing
depolymerized microtubules. All samples were processed and assayed using previously
described standard liquid scintillation techniques[ 1]. Statistical significance was
evaluated using a two-tailed Student's t-test with comparison to control cases.
Drug and binding site distribution radially through the arterial wall were
correlated. Radiolabeled drug content in 40gm transmural sections was spatially mapped
to tissue immunostained for the binding proteins - tubulin or FKBP (both antibodies from
BD Bioscience, San Jose, CA). FK506, colchicine or the indicated non-labeled control
competitor drugs (labeled rapamycin plus non-labeled paclitaxel and vice versus) were
loaded in tissue at a three log order molar excess over the labeled drug concentration to
maximize competitive displacement effects.
64
Specific Protein Binding Assays
Combinations of radiolabled rapamycin and human wild type FKBP protein
(generously donated by Ariad, Cambridge, MA) at 1:1 molar ratios were equilibrated for
one hour with competitor drugs at molar ratios ranging from 1:1000 to 1000:1. Solutions
were purified through a lipophilic Sephadex column (Sigma-Aldrich, USA) to isolate
labeled rapamycin bound to FKBP. Paclitaxel polymerization assays were performed
using standard optical density spectrophotometry methods with measurements at 340nm
and tubulin concentrations of lmg/ml. In brief, purified tubulin (Cytoskeleton, Denver,
CO) was mixed with GTP, paclitaxel and a competitor drug (with the exception of the
control sample). Samples were allowed to polymerize for one hour at 32C with optical
density measurements made at the beginning and end of the experiment. All data were
corrected for absorbance of the competitor drugs by subtracting off the signal
contributions of the individual drugs.
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3.3 Results
Drug Competition in Local Delivery
Bovine carotid arterial tissue preparations were incubated for 24 hours in 10-6 M
paclitaxel or rapamycin along with the indicated competitor drug at a three log order
molar excess (Figure A). Rapamycin displaces 35% of the labeled paclitaxel from
tissue specimens while paclitaxel blocks only 50% of rapamycin binding. FK506 has no
significant effect on paclitaxel loading but eliminates 50% of the binding capacity for
rapamycin, likely through occupying sites on the specific binding protein FKBP in the
tissue. Similarly colchicine significantly decreases paclitaxel uptake by -50% but had a
statistically insignificant effect on rapamycin uptake.
To elucidate the mechanisms of displacement tissue samples were preloaded with
only the competitor drugs for 24 hours. Following this incubation period, tissue was
moved to a separate bath containing 10-6 M paclitaxel or rapamycin for an additional 24
hours. Only colchicine pre-incubation reduced paclitaxel binding, otherwise the tissue
loading did not significantly differ from no-competition controls (Figure B). Previously
we have shown that hydrophobic species such as paclitaxel and rapamycin, and
hydrophilic dextrans [1] elute out of tissue to steady state levels over a period of
approximately 12 hours. These results imply that the pre-incubated competitor drugs
elute out of tissue and/or are displaced by paclitaxel and rapamycin, allowing the labeled
drugs to achieve their full tissue loading potential. In the colchicine-paclitaxel case, it
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appears that colchicine remains sufficiently associated with tissue proteins to reduce the
overall paclitaxel tissue levels.
Dose response curves were constructed to evaluate local competition between
paclitaxel and rapamycin. Paclitaxel (Figure 2A) and rapamycin (Figure 2B) at 10-6 M
were both simultaneously incubated with varying doses of paclitaxel and rapamycin.
When labeled paclitaxel is loaded with unlabeled paclitaxel, significant displacement of
the labeled drug is noted at concentrations between 10-6M and 10-5M. For paclitaxel
loading with rapamycin, significant displacement of drug does not occur until the
concentration of rapamycin is between 10-4M and 10-3 M. Similar results are observed
when assaying rapamycin characteristics. For both cases, three log order molar excess of
unmatched drug is required to reduce binding of the labeled drug significantly. Arterial
concentrations from stent delivery in porcine models typically yield tissue concentrations
between 10-8M and 10-7M. At 10-8 M loading of labeled drug, competition drug
concentrations still must reach between 10-4M and 10-3M to displace significantly the
labeled drug (data not shown). Tissue drug concentrations of 10-3M have never been
reported from paclitaxel or rapamycin-eluting stents.
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Figure 3.1: Specific and General Binding Competition
(A) Percentage of paclitaxel () and rapamycin () in tissue
relative to no-competition controls after 24 hours when
simultaneously loaded with various competitor drugs
(indicated in the figure) and (B) when tissue was exposed to
competitor drug for 24 hours followed by a separate 24 hour
loading of the labeled drugs. (*) indicates a statistically
significant difference (p < 0.05 with a two-tailed Student's t-
test) from the no-competition control. Standard deviations
are plotted with the data set. tissue loading profile of
radioactive dextran (), paclitaxel () and rapamycin (0) in
bovine internal carotid tissue segments.
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Figure 3.2: Paclitaxel and Rapamycin Tissue Binding Competition
(A) The percentage of control radiolabeled paclitaxel bound in tissue when in
competition with unlabeled paclitaxel () and unlabeled rapamycin (0). (B)
The percentage of control radiolabeled rapamycin in tissue when in
competition with unlabeled paclitaxel () and unlabeled rapamycin (0).
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Specific and General Binding Tissue Domains
Transmural distributions of rapamycin (Figure 3) and paclitaxel (Figure 4) under
conditions of specific and general displacement were plotted over tissue sections
immunohistochemically labeled for each drugs' specific binding target and normalized to
their control profiles. We have previously shown that rapamycin maintains a
homogenous transmural distribution across the width of arterial tissue while paclitaxel
distributes more variably, with relatively higher sub-intimal and adventitial binding and
lower medial deposition[1]. We now differentiate between specific and general tissue
binding. Colchicine, reduced normalized paclitaxel content by - 50% in a uniform
manner across the media and adventitia, despite a seemingly higher density of tubulin
staining paclitaxel-binding sites in the media. In contrast, rapamycin forced the paclitaxel
transmural profile to drop precipitously from 70% in the media to nearly 30% in the
adventitia, indicating increased blockade of general binding sites by rapamycin in the
outer vessel wall. The rapamycin profiles followed similar trends to those observed with
paclitaxel. When FK506 inhibited specific binding of rapamycin to tissue, medial drug
concentrations decreased as expected. Paclitaxel reduced general binding in the
adventitia relative to the media. For both rapamycin and paclitaxel, specific displacement
of the drug correlates with a higher density of the specific protein binding target in the
media, while general displacement is stronger in the adventitia where the specific binding
site concentration is decreased. Together these profiles indicate that both specific and
general binding are found in the media and adventitia but with stronger specific binding
trends in the media for both drugs.
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Fi2ure 3.3: Transmural Paclitaxel Distribution with Competition
Transmural equilibrium distribution of radioactive paclitaxel plus colchicine
(0) or rapamycin (0) in 0.040mm thick bovine internal carotid tissue
segments plotted over arterial tissue stained for tubulin protein (tubulin
immunostain dilution 1:50). Each data point is normalized to no-competition
profiles[1].
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Fhmre 3.4: Transmural Rapamvcin Distribution with Competition
Transmural equilibrium distribution of radioactive rapamycin plus FK506 (0)
or pac1itaxel (D) in 0.040mm thick bovine internal carotid tissue segments
plotted over arterial tissue stained for FKBP (FKBP immunostain dilution
1:10) Each data point is normalized to no-competition profiles[ 1].
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Local Molecular Specificitv
FKBP and tubulin binding assays were used to assess molecular binding
specificity. Increasing concentrations of paclitaxel did not disrupt rapamycin binding to
FKBP. These data imply that paclitaxel does not specifically bind to the rapamycin
binding domain on FKBP and that paclitaxel and rapamycin do not associate with one
another to decrease the amount of rapamycin available for binding (Figure 5). As
expected unlabeled rapamycin and FK506, which share the same binding domain on
FKBP, do have a competitive effect. Similarly only colchicine, a tubulin depolymerizing
agent, alters the polymerization state of tubulin in the presence of paclitaxel while
rapamycin has no effect (data not shown).
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Systemic to Local Competition
A number of drugs commonly administered to patients with cardiovascular
diseases were simultaneously loaded in tissue with labeled paclitaxel or rapamycin.
Notably, insulin, captopril (ACE-inhibitor), atenolol and metoprolol (beta blockers) all
significantly reduce arterial drug levels, likely by displacing labeled drug from general
binding sites or offering alternative binding domains as may be the case with insulin.
Salicyclic acid (aspirin), nifidipine (calcium channel blocker), hydrochlorothiazide
(diuretic) and clopidogrel (anti-platelet) showed no significant reduction in drugs levels.
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Figure 3.6: Systemically Delivered Drug Competition
(A) Percentage of radiolabeled paclitaxel () and rapamycin () relative to
no-competition controls in tissue after 24 hours when simultaneously loaded
with various unlabeled competitor drugs (indicated in the figure). (*)
indicates a statistically significant difference (p < 0.05 with a two-tailed
Student's t-test) from the no-competition control. Standard deviations are
plotted with the data set.
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3.4 Discussion
DES are now the clinically dominate intervention for treating occlusive coronary
vascular pathologies, and yet full mechanistic definition of their success and
shortcomings remain elusive. Specificity in binding has emerged as a vital component of
DES functionality with competition for binding space a critical factor in arterial drug
uptake. We now report the potential competitive effects on DES tissue deposition by
other compounds released from adjacent stents or circulating after systemic
administration.
Local/Local Competition
Paclitaxel does not interfere with rapamycin binding to FKBP, and rapamycin
does not perturb paclitaxel associations with tubulin. Each drug can displace the other
from tissue but only at surrounding concentrations on the order of 10-3 M. Such high
molar concentrations of drug may be relevant for systemically delivered therapies, but are
not likely observed after elution from multiple proximate stents even if all of the drug on
the stents would pool locally. In the context of overlapping stents, the question of
rapamycin-paclitaxel drug competition remains an open and clinically relevant question.
In certain scenarios, placement of two stents with different drug formulations may be
favored over placing two identical devices. Additionally, a multi-drug combination stent,
e.g. paclitaxel-rapamycin, may prove more efficacious than single drug therapies. Our
investigations show no physiochemical contraindication to placing a pair of dissimilar
DES in close proximity or placing two different drugs on the same stent. As more
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models of drug-eluting stents with different drug formulations emerge, these types of
interactions may be therapeutically pertinent and should be considered in the evaluation
of therapeutic viability.
Though DES has significantly reduced the number of restenosis cases, an
appreciable proportion of patient population still manifest this condition[ 1-13]. No
study has yet isolated the mechanism(s) of failure beyond identifying risk factors such as
diabetes, previous interventions, lesion morphology, lesion dimension and vascular bed
geometry[14]. Our models for specific protein binding inhibition with FK506 and
colchicine demonstrate that variations in specific binding site availability significantly
affects tissue uptake. Disease states such as diabetes or atherosclerosis may directly
affect FKBE' expression or tubulin polymerization, pathologically altering specific
binding site availability and drug uptake capacity. In our model systems, blockade of
general binding sites also reduces total tissue binding capacity. General binding sites
throughout the tissue may serve as a reservoir for locally delivered drugs after the stent
platform is depleted. Pathologic loss of general binding domains can also reduce overall
tissue capacity.
Local/Systemic Competition
Systemically delivered compounds can maintain blood levels several log orders
higher in concentrations than locally delivered drug tissue levels. The competitive
displacing effects of systemically circulating drugs appear to be at the level of general
78
binding. Since general binding sites reside in both the media and adventitia, systemic
drug competition may reduce drug distribution levels throughout the vessel wall.
Heterogeneity exists between different screened compounds with regard to their overall
effect on drug deposition and even between paclitaxel and rapamycin loading. The
individual properties of each drug may have specific properties which favor general
binding site displacement.
Conclusions
Local drug delivery maintains great appeal for many pathologic conditions. In
vascular systems at the level of local/local competition, rapamycin and paclitaxel do not
appear to interfere with the other's specific binding to the therapeutically relevant tissue
proteins. However, systemic drugs can displace local stent-eluted compounds from
general binding sites and decrease tissue reserve capacity. As the applications and
combinations of drug formulations for local and systemic drug delivery expand, the
competition implications of concomitant delivery must be consider to optimize delivery
methodologies.
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Chapter 4
Binding, Microenvironment and Drug Delivery
Abstract
Drug-eluting stents deliver potent compounds directly to arterial segments but can
become clot-laden when deployed. The question arises as to whether thrombi affect drug
elution and arterial uptake. Paclitaxel transport and retention was assessed in clots of
different blood components. Diffusivity, affected by clot organization, is fastest in fibrin
(- 347 !tm2/s), slower in fibrin-red cell clots (34.98 tm 2/s) and slowest in whole blood
clots (3.55 gm 2/s). Blood cells bind and retain Paclitaxel such that levels in clot increase
linearly with red cell fraction. At physiologic hematocrit, clot retains 3 times the amount
of Paclitaxel in surrounding solutions. Computational models predict that the potential of
thrombus to absorb, retain and release drug, or to act as a barrier to drug delivery depends
on clot geometry and strut position in clot relative to the vessel wall. Clot between artery
and stent can reduce uptake 10-fold, while clot overlying the stent can shield drug from
washout, increasing uptake. Model assumptions were confirmed and predictions
validated in a novel rat model that introduces thrombosis within stented aortae where
non-occlusive thrombus acts as capacitive space for drug and shifts drug levels to
decrease tissue uptake 2-fold. Thrombus apposed on stents creates large variations in
drug uptake and can act to either increase or decrease wall deposition depending on the
clot and stent geometry. Arterial deposition of drug from stents deployed in clots will be
highly variable and unpredictable unless the clot can be adequately controlled or
removed.
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4.1 Introduction
The reduction of intimal hyperplasia in an arterial segment by drug-eluting stents
[1-3] depends on appropriate drug dose distribution in the arterial wall over an extended
period of time[4-7]. While several experimental and computational studies have
examined the local pharmacokinetics of stent-based drug delivery[7, 8], none have
considered how thrombus in the vicinity of the stent affects drug elution and subsequent
tissue deposition. Stents are often directly deployed at sites of thrombosis[9], and clot
inevitably develops after implantation once struts become coated with plasma
proteins[10-13]. In most cases the thrombus is not angiographically apparent or clinically
evident, as occlusive thrombosis rates for drug-eluting stents are low, approximately 1-
4%[10, 13, 14]. Nevertheless, even a fine layer of material directly apposed to a stent
strut can significantly transform the drug-eluting performance of the stent[15], and
consequently alter the drug distribution in the arterial wall.
The influence of thrombus on the arterial distribution of Paclitaxel delivered
continuously from a drug-eluting stent was considered by examining how the
composition of clot affects drug transport. Since thrombus naturally remodels over
time[10-12] we hypothesized that clot capacity and transport properties for Paclitaxel
should evolve with the shift in clot organization and components. Additionally, we
hypothesized that distribution of drug in the target blood vessel will depend on the
geometry of the clot and the relative positioning of the overlying stent struts within any
thrombus. Computational models simulating elution from a clot-covered stent revealed
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complex behaviors. Given the vagaries of clot-strut positioning and clot composition,
arterial levels of stent-eluted drug may fluctuate by orders of magnitude with variations
in clot properties, implying an inherent uncertainty in predicting arterial drug levels if
clot dimensions are not locally controlled. Clot carefully created over stents in a rat aorta
verified model predictions by serving as a capacitive barrier, limiting uptake, and not
simply as a passive conduit for drug.
Implantation of drug-eluting stents in the setting of thrombus presents a unique set
of challenges as the irregularity of clots can cause large alterations in arterial drug uptake.
Clot removal prior to stent deployment might reduce such variability and ensure greater
control of the distribution of therapeutic drug levels within the arterial wall.
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4.2 Methods
Preparation of Fibrin and Whole Blood Clots
Clots of varying compositions were prepared to examine drug transport through
and binding to thrombus at different stages of development. Based on established
methods[16], clots were prepared by mixing human fibrinogen (Calbiochem), thrombin
(Calbiochem), and coagulation factor XIII (Calbiochem) with appropriate proportions of
human packed red cells (Rhode Island Blood Center, Providence). These preparations
allowed for measurement of diffusivities and drug capacity for different clot
compositions. To create pure fibrin clots, 100 ptL of stock 3 mg/mL fibrinogen were
mixed with 100 pL of stock 6 U/mL thrombin and 100 ptL of stock 0.27 U/mL Factor
XIII, resulting in a final clot volume of 300 tL and final clot concentrations of 1 mg/mL
fibrinogen, 2 U/mL thrombin and 0.09 U/mL Factor XIII. To create clots of different red
cell volume fractions, more concentrated stock solutions of fibrinogen, thrombin and
Factor XIII were used so that the final clot concentrations of these components did not
vary after adding human packed red cells at 9%, 25% or 50% by volume. Each mixture
was allowed to coagulate for at least 2 h at 37 °C before experimentation. For whole
blood clots, 300 tL aliquots of fresh blood were drawn from the middle ear artery of New
Zealand white rabbits (3-5 kg), placed into culture plate wells, and allowed to coagulate
for at least 2 h at 37 °C before experimentation.
Transport Measurements
Paclitaxel transport in thrombus was characterized by a diffusivity and convective
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velocity, and binding or retention capacity of tissue relative to clot, and of clot relative to
surrounding solution (Figure 1).
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Fieure 4.1: Transport Parameters
Transport parameters for a clotted stent strut: Dc/ot
and Dtiss are drug diffusivities in clot and tissue, V is
drug convective velocity, Kc/ot:sol is drug capacity of
clot relative to solution, Ktiss:sol is drug capacity of
arterial tissue relative to solution, and Ktiss:c/ot is the
drug capacity of arterial tissue relative to clot.
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Drug Capacity
We determined the ratio of clot drug capacity relative to solution drug capacity
(Kcot:solution) for different clot compositions. Whole blood and fibrin-red cell clots were
prepared in 48-well tissue culture plate wells as described above and covered with 300
gLL of [3H]-Paclitaxel (Sigma) (1.06 x 10-8 mmol/mL) dissolved in 7.5 U/mL hirudin
(Calbiochem) in phosphate-buffered saline (PBS, Sigma) to prevent coagulation of the
drug solution. The potential effects of circulating protein drug adsorption on binding
capacity was simulated with the addition of 4% bovine serum albumin (Sigma) to the
drug solution. The clot was incubated with drug for 72 h, a period determined in separate
experiments to be sufficient to approach tissue equilibrium. Clots were washed in PBS,
dissolved for 48 h in 400 gL of Solvable (Packard-Canberra) and treated with 30% H202
(Mallincrokdt) in a 1:8 ratio. Drug content was measured using a liquid scintillation
counter (2500 TR, Packard-Canberra) with 10 mL scintillation cocktail (Ultima Gold,
Perkin-Elmer). Drug capacity of the clot was taken as the ratio of drug concentration in
the clots referenced to final drug concentration in the source solution. Assuming specific
and nonspecific drug binding interactions in tissue are independent of those in clot, we
can estimate Ktissue:clot, the ratio of tissue drug capacity relative to clot drug capacity from
Kclot:solution as:
Ktissue:clot = Ktissue:solution / Kclot:solution [ 1 ]
using previously reported values of Ktissue:solution for Paclitaxel[ 17].
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Drug Diffusivity
Fresh rabbit blood and fibrin-red cell mixtures were coagulated in 12-well tissue
culture plates using a clot volume of 2 mL per well. Care was taken to minimize air
bubbles, and larger well diameters were chosen to reduce the effects of meniscus
formation. [3H]-Paclitaxel (1.06 x 10-8 mmol/mL, 2 mL/well) in 7.5 U/mL hirudin was
allowed to diffuse into the clot for up to 1 h. Following the diffusion phase, clots were
washed in PBS and dissolved for 48 h in 2.1 mL of Solvable. After treatment with 30%
H 20 2, clot drug content was measured using a liquid scintillation counter with 10 mL
scintillation cocktail. Drug diffusivity was determined by fitting the measured total clot
drug content with the numerical solution of the diffusion equation[7, 18] for a constant
drug source concentration boundary condition.
Drug Convective Velocity
While drug is efficiently transported through isolated clots[16] drug convective
velocity in clots juxtaposed to the arterial wall is restricted at steady-state by continuity to
match the slower transport through the arterial wall. Paclitaxel convective velocity was
determined in 4-5 cm segments of bovine calf carotid arteries connected to tubing on one
end and sealed on the other. [3H]-Paclitaxel (1.06 x 10-8 mmol/mL) was infused at
pressures of 60 and 90 mmHg. After 2 h, drug content in a 6 mm diameter biopsy punch
of the arterial wall was measured. The source drug concentration, arterial drug content,
convection time, biopsy punch dimensions, and tissue [3H]-Paclitaxel diffusivity and
capacity [17, 19] were fit to a drug diffusion-convection model [7, 18]. Convective
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velocity increased three-fold, from 3.2 to 9.2 nm/s, for a 50% increase in transmural
pressure from 60 to 90 mmHg.
Continuum Pharmacokinetics Modeling of Thrombus Transport
Drug release from a stent and transport within the thrombus and arterial wall were
modeled using the diffusion-convection equation and a steady-release boundary condition
(see appendix for code). We limited our analysis to a two-dimensional cross-section of
the artery and clot, a 100 x 100 ptm strut, and assumed rapid luminal washout, no
endothelial resistance, and a perivascular sink. We used zero concentration boundary
conditions on the endovascular and perivascular aspects of the artery, and symmetry
boundary condition in the planar directions. We further assumed an arterial wall
thickness of' 800 m and a strut-to-strut distance of 1000 tm. Simulations were
performed in Cartesian coordinates. In such a system, transport of soluble drug is
described as:
au a D au + a DY , au[2]
dt Ax axY y2]
where U is fi-ee drug concentration, and V is the transmural convective velocity. Dx and
Dy are diffusivities in the planar X and transmural Y directions, and within the arterial
wall the former was three orders of magnitude larger than the latter (37.2 vs. 0.021 gim 2/s)
[17, 19]. Free drug concentration is related to total concentration (C) by the tissue
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capacity of the drug (K), so that C = K U . Because of the multi-component structure of
the clot-artery system, K, Dx and Dy are experimentally determined for each component
of the system. V was taken as 9.2 nm/s, corresponding to our measured drug convective
velocity at 90 mm Hg of transmural pressure. Simultaneous transport and binding was
implemented using operator splitting. During each time step, free drug released from the
stent was allowed to diffuse and convect along with free drug already in the system. We
thus first compute an intermediate post-transport free drug distribution (P) and then
calculate the free (U) and total (C) drug concentrations at the start of the next
computation cycle to account for differential drug capacity:
C (t - lt) = C(t) + C = C(t) + (P- U(t)) = C(t) + P- C(t) /K [3]
U (t + At) = U(t) + U = U(t) + C/K
= U(t)(P-U(t)) /K = (C(t) + P) /K- C(t) /K2 [4]
We examined the theoretical total arterial drug content for a range of clot widths
(100 to 900 pm), heights (50 to 450 jum), and stent strut distances from the arterial
surface (0 to 350 m). We considered clots composed of pure fibrin, 50% packed red
cells or whole blood, with clot transport and drug uptake properties based on our
experimental measurements for Paclitaxel. We further simulated clots with varying drug
diffusivities and capacities to assess the specific effects of these parameters on arterial
drug content.
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Arterial drug content was expressed as an arterial drug ratio, defined as the total
arterial drug deposition achieved by a specific stent-thrombus configuration normalized
to the total arterial drug deposition achieved by a non-clotted drug-eluting stent directly
apposed against the arterial wall. An arterial drug ratio greater than unity implies a
greater amount of drug in the arterial wall relative to that achieved by a non-clotted drug-
eluting stent. Simulations were run at a resolution of 50 m per computational node.
Finer mesh resolutions were tested for a number of cases and did not qualitatively change
the simulation results. The model was run until steady-state drug levels were achieved
both in the thrombus and in the arterial wall.
In vivo Thrombus Model
Paclitaxel uptake was evaluated in stented abdominal aortae of adult male
Sprague-Dawley rats (500-700 mg, Charles River Laboratories) in the presence and
absence of controlled induced mural thrombus. Procedures were in accordance with the
guidelines of the American Association for the Accreditation of Laboratory Animal Care
and the NIH. Under inhaled isofluorane anesthesia the right femoral artery was exposed,
ligated and incised proximally to allow passage of a 0.014" angioplasty guide into the
aorta. The abdominal aorta was exposed, and a 15mm segment above the origin of the
renal arteries was ligated proximally and distally. Thrombus formed within 10 minutes in
the isolated aortic segment, and the proximal aortic ligature was removed. A 2.625 mm
steel stent (MULTI-LINK PIXEL, Guidant) was rapidly passed into the thrombosed
segment and deployed for 15 seconds at 10 atm. The distal ligature was removed and
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after visually insuring adequate blood flow in the aorta with no macroscopic evidence of
aortic ischemia, the balloon and wire were removed, the femoral artery ligated proximal
to the arteriotomy, and both incisions closed.
Control animals underwent abdominal aortic stenting utilizing a similar technique
without aortic thrombus formation. Heparin (100 U/kg) was administered IV before
stenting only to the control rats. Aspirin (5 mg/kg/day, per standard practice in this type
of procedure) was added to drinking water immediately post surgery to all animals for the
duration of the experiment. Paclitaxel was administered intra-peritoneally three times at 5
mg/kg every 12 hours with the first injection immediately after stenting. Animals were
sacrificed 30 hours after stenting with inhaled CO2. The aorta was pressure perfused with
isotonic saline, cleaned of adherent fat and connective tissues and the stented segment
detached. The stent was carefully removed and the tissue, stent and overlying thrombus
were snap-frozen with liquid N2. Paclitaxel in the arterial wall and excised thrombus was
determined using a commercial immunoassay (Hawaii Biotech). Paclitaxel uptake in the
stented region was normalized to uptake in a non-stented region and compared for cases
with clot absent and clot present. Additionally, segments of the stented vessels were
excised and histologically processed with verHoff's tissue elastin stain.
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4.3 Results
Influence of Thrombus Geometry on Arterial Paclitaxel Uptake
Arterial Paclitaxel distribution is exquisitely sensitive to changes in the local
geometry of' the overlying thrombus. Strut position within the clot determines uptake
(Figures 2A-D). When there is a greater mass of clot over the strut, the strut sits close to
the wall and the overlying clot shields against systemic washout. Arterial drug uptake can
rise 30-fold higher than if clot were not present. Conversely when the bulk of the clot is
interposed between the strut and artery a barrier to transport is created that decreases
arterial drug uptake. For some geometries these forces balance. Indeed the clot can grow
in height, surface area or both to alter uptake. Arterial drug uptake peaks at a clot height
to width ratio of- 0.3 when clot dimensions were varied and clot volume kept constant
(Figure 2D). Radial and longitudinal washout increases at other ratios lowering drug
uptake. Given the natural variability of thrombosis in vivo such sensitivity to geometry
implies arterial drug uptake from drug-eluting stents deployed in clotted arterial segments
may also be highly variable.
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Fi2ure 4.2: Clot and Stent Position in Dru2 Uptake
For 50% fibrin-red cell clots (A), pure fibrin clots (.), and whole blood clots (_),
arterial drug ratios (total drug in artery from clotted stent vs. total drug in artery from
non-clotted stent) were computed vs. changes in (A) strut-artery distance, with a clot
of fixed dimensions, (B) clot height, with strut at base of clot, (C) clot height, with
strut at top of clot, (D) clot thickness to width ratio, with constant clot size and strut
position.
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Paclitaxel Deposition and Transport in Fibrin, Fibrin-Red Cell and Whole Blood Clots
Paclitaxel diffusivity is retarded by fibrin clots once organized by addition of
thrombin. Diffusivity decreases by half to 347±14 !tm2/s when thrombin sufficient to
induce crosslinking is added to fibrinogen and by an additional order of magnitude when
red blood cells are present (Figure 3A). Until red blood cells are present the Paclitaxel
capacity of fibrin clots is no different from the capacity of buffer solution (Kfibrin:solution =
0.94±0.11), irrespective of thrombin concentration and degree of crosslinking thrombin
induces (data not shown). Clots with 50% red cells retain nearly 3-fold more drug than
pure fibrin clots (Kclotsolution = 2.92±0.26, p < 0.05, Figure 3B). Paclitaxel capacity
increases dramatically and in a linear fashion as the red cell fraction in the clot increases.
Mature or chronic thrombotic masses are more heterogeneous than fibrin-red cell
clots. The fibrin meshwork in these clots contains platelets and other blood elements,
adding further restrictions on drug transport. Paclitaxel diffusivity in whole blood clots is
an order of magnitude lower than that in 50% fibrin-red cell clots (Dfibrin-red cell clot =
34.98±10.3 Lm2/s vs. Dwhole blood clot = 3.55+0.75 !tm2 /s, Figures. 3A and 4A). The
Paclitaxel capacity of whole blood clots is however remarkably close to that expected of
a fibrin-red cell clot with physiologic hematocrit (Klot,:solution = 2.63±0.17, Figure 4B).
Thus, non-red cell components of blood delay drug transport but do not add substantially
to the ability of fibrin and red cells to retain drug within clot. The protein binding nature
of Paclitaxel has an effect as well. The presence of albumin in the drug solution reduced
the binding of drug by red blood cells. Whole blood clot Paclitaxel diffusivity increased
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when albumin was present (Figure 4A) while capacity was reduced to near unity (Figure
4B).
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Figure 4.3: Paclitaxel Diffusivity and Capacity in Clot
(A) Paclitaxel diffusivity in fibrin-red cell clots vs. red cell
fraction (** indicates statistically significant difference p <
0.05 compared to pure fibrin). (B) Paclitaxel capacity in
fibrin-red cell clots relative to capacity in solution vs. clot red
cell fraction.
98
oU 
m-
U..n EI
* .C0 ! 0P. i
01-1 1
__Ir_ __Ir_ L
I
A B
uU
U o..2
** =
U ° 
. 20
U'
M
ILo
a.
Blood clot Blood clot Blood clot Blood clot
(+BSA) (+BSA)
Figure 4.4: BSA and Paclitaxel Transport
(A) Paclitaxel capacity in whole blood clots relative to
capacity in solution buffer with and without bovine serum
albumin (BSA). (B) Paclitaxel diffusivity in whole blood
clots with and without BSA in drug source. For both data sets
in this figure, ** indicates statistically significant difference
p < 0.05.
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Influence of Clot Diffusivity and Capacity on Arterial Paclitaxel Uptake
Modeling allows us to investigate how drug retention capacity and diffusivity
independently influence arterial drug uptake for stent struts adjacent to the arterial wall in
the midline of an invariant clot. This type of analysis can be used to understand how
drugs with transport and capacity characteristics different from Paclitaxel will behave.
Drug levels are maximal when drug diffusivity in the clot is at, or below, transmural drug
diffusivity in the arterial wall (0.021 pm2/s for Paclitaxel[19]). Arterial drug uptake will
decrease in a sigmoidal fashion if drug can diffuse more freely in the clot (Figure 5A).
This prediction is consistent with heightened arterial drug uptake for arteries embedded
with stents surrounded by whole blood clots where diffusivity is lowest, and low uptake
for stents surrounded by fibrin clots where diffusivity is maximized. Arterial drug loading
is determined by more than diffusivity. For two drugs of identical clot diffusivities
arterial uptake is delayed for the one which is more highly retained in the clot. Greater
interactions of drug with clot components retard drug release from the clot (Figure 5B).
However, with a continuous drug source from the stent, identical steady-state arterial
drug content is eventually reached, independent of clot drug retention capacity, albeit at
different time points.
100
1.00
B
A
0.25 0.50 0.75
Simulation Time
0.01 0.1 1 10 100 1000
Drug Diffusivity in Clot (um2/s)
0%
0.00
"'i 50%
'C:
CD
"t::
<
"'C
CD
"'iu
(J)
-c:
.!100%c:oo
C)
~...
~ 50%
'C:
CD
1::
<
"'C
CD
"'i 0%
~ 0.001
-c:
.! 100%c:oo
C)
~...c
Fi2ure 4.5: Variable Diffusivitv and Capacity in Uptake
(A) Steady-state total arterial drug content (scaled to total
drug content at D = 0.001 J.lm2/s) as a function of clot drug
diffusivity, with clot dimensions and capacities held
invariant. (B) Normalized total arterial drug content vs.
simulation time, for relative Paclitaxel capacities of Kclot:sol =
3 ( • ), Kclot:sol = 100 (.) and Kclot:sol = 300 (£.).
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Thrombus and Paclitaxel Uptake In vivo
A novel model of controlled in vivo thrombus was developed for this study. These
experiments in rats confirm that clot possesses capacitive properties for sequestering
Paclitaxel. Clot does not simply pass drug through to the underlying artery after stent
release, it alters arterial wall uptake. All stented aortas, control (Figure 6A) and clot-laden
(Figure 6B), appeared viable with no evidence of necrosis or ischemia at sacrifice.
Control animals had no notable thrombus in stented aortae at implantation, and upon
device excision no clot present on the stent or the luminal surface of the vessel wall.
Mural thrombus was present only after controlled induction, covering the stent struts
without occluding the aortic lumen or affecting blood flow. A visible thrombotic mesh-
like mass was attached to the stent struts and was excised with the stent. The thrombus
was a heterogeneous composite of fibrin, platelets and red blood cells. The control and
thrombosed stents were placed in a 20% ethanol solution with Tween 20 and vortexed for
15 minutes, a time period sufficient to dissolve the clot. The drug content on the
thrombosed stents was significantly (p < 0.05) greater than the control devices (Figure
7A). This capacitive action of clot can both limit transport at the arterial wall interface
and retard systemic washout depending on clot geometry. In our in vivo studies, arterial
drug uptake in the presence of clot was significantly (p < 0.05) reduced by -50% in
stented vessels in comparison to the control devices (Figure 7B).
Systemic delivery via intraperitoneal administration is equivalent to a non-zero
Dirichlet luminal loading condition, a situation most analogous to the computational
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model with the stent strut adjacent to the lumen (Figure 2C). When the in vivo clot
dimensions were determined and used as boundary conditions and input parameters the
model predicted an arterial drug ratio of 0.56, strikingly close to the 50% decrease in
arterial uptake seen in the animal model. In this case, drug recycles between the
thrombus and the lumen more effectively than it passes from the clot to the tissue wall,
reducing arterial drug uptake. As predicted, thrombus is not merely a passive medium,
but rather a capacitive space to retain drug and shift the drug deposition distribution.
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Fi1:wre 4.6: verHoff's Stainine of Stented Rat Abdominal Aorta
(A) verHoffs staining of control stented rat abdominal aorta. (B) verHoffs stain of
experimental mural thrombus in rat abdominal aorta. Thrombus (immediately adjacent to the
darkly stained elastic laminae) is composed of fibrin, platelets and red blood cells, extends
approximately 300Jlm in to the lumen and is non-occlusive.
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Figure 4.7: Paclitaxel Uptake and Thrombosis
(A) Paclitaxel eluted from stents in ml of 20% ethanol solution. (B) Paclitaxel deposition in
stented rat abdominal aorta normalized to deposition in non-stented rat thoracic aorta. For
both data sets in this figure, ** indicates statistically significant difference p < 0.05.
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4.4 Discussion
Thrombosis is a feature of the acutely occluded artery and a catastrophic failure
mode for endovascular devices. Drug elution increases the potential for subacute stent
thrombosis. We now show that clot, even non-obstructing microthrombi, can affect drug
deposition. Our physiologic and computational models demonstrate that clot changes the
local environment of the stent strut and physiological transport forces[7, 8] to alter
arterial wall drug uptake and retention[6, 17, 20]. Small amounts of local thrombus
produce significant variations in arterial drug levels depending on clot geometry and
composition. Because of the unpredictability of these factors in the clinical setting,
deployment of a drug-eluting stent in a clot-laden arterial segment will inevitably lead to
variability in arterial drug distribution, potentially affecting clinical outcome.
Transport Forces in the Clot Affect Arterial Drug Uptake
There exists a balance between the capacity of an artery to absorb a drug and the
rate at which the drug is presented to the arterial tissue. Clot alters this balance by
absorbing drug and retarding transport. Alterations in both capacity and diffusivity will
likely change arterial drug levels during therapeutic delivery by modifying the amount
and the rate at which drug can enter the vessel wall. Paclitaxel moves more slowly
through clots with higher red cell content because of repeated binding and release from
nonspecific and specific cellular components like tubulin[21] which are ubiquitous within
tissue and red cells. Whole blood clots present a denser platelet-fibrin meshwork which
further hampers drug transport. Diffusivities change with clot content and drug. The
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steady-state arterial uptake of a given drug will be maximized when the drug diffusivity
through a specific clot is slower than its diffusivity in arterial tissue. In this case clot
retains drug within the local vicinity of the vessel wall allowing for increased contact
time and potential infiltration and distribution through the arterial wall. At higher clot
diffusivities drug is delivered to the artery more quickly than can be absorbed, and a
greater fraction of the drug cannot be bound before it is lost to the circulation.
Clot is therefore a double-edged sword for drug-eluting stents. In some scenarios
the capacitive and binding phenomena will increase tissue uptake and in others reduce it.
The problem is that thrombosis is unpredictable and irregular. Indeed, the DELIVER trial
of non-polymeric rapidly eluting Paclitaxel stents supports the potential beneficial impact
of clot on drug-eluting stents. Patients who received Paclitaxel-eluting stents and
glycoprotein-IIb/IIIa inhibitors had significantly higher rates of restenosis than those
patients who received only the drug-eluting stent without the inhibitor[22]. It is possible
that the glycoprotein inhibitor removed or reduced thrombus around the stent struts. In
this specific case where the drug was so rapidly eluted off of the stent the capacitive-like
properties of clot might serve as a secondary release platform. Here clot may reduce
systemic washout and preserve drug for presentation to the arterial wall. In systems
where polymeric coatings are designed specifically to elute drug into tissue over time,
extended retention in clot may enhance systemic dilution. More consistent clinical results
may thus be expected if clots are both removed from the target arterial segment before
stent deployment and carefully regulated after interventions.
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Drug Interactions with Clot
Just as arterial ultrastructure influences arterial drug uptake[6, 17], the
organization of thrombus affects the capacity to store and release Paclitaxel to the arterial
wall. Clots with more red cells absorb greater amounts of drug as a result of an increase
in both nonspecific and specific interactions. These same interactions however also retard
arterial drug uptake kinetics. Most of the Paclitaxel in high capacity clots is bound, and
since only free drug can diffuse[7, 19], delivery to the artery slows when drug passes
through clot before it contacts the arterial wall. Drug capacity in clot thus helps determine
drug uptake kinetics in arteries. The rate of drug transport in clot influences the extent to
which the clot can retard systemic drug washout. Effective drug transport distances are
determined both by the drug transport coefficients within the clot and by the geometric
dimensions of the clot. Net arterial drug uptake is governed by a balance of drug retention
in the clot, drug transport from the clot to the systemic circulation and from the clot into
the artery. Clot-stent geometry determines which of these competing processes dominate.
This fundamental mechanism must be considered for optimizing drug-eluting stent
therapies.
The importance of binding was demonstrated further by the competition
established by BSA. High levels of circulating proteins can act as an enhanced sink for
drug that does not interact with the arterial wall beneath a strut or with clot. The
competition for drug between blood and blood vessel is amplified in vivo and the ability
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of clot to retain and retard drug is all the more critical for protein binding compounds. In
this regard specific and nonspecific binding in arterial systems are major determinants of
tissue transport and uptake for both Paclitaxel and Rapamycin[20]. Polymerized
microtubules in red blood cells and smooth muscles bind Paclitaxel with nanomolar
specificity. At similar concentrations in the same cell types, the FK506 binding protein
also shows nanomolar binding specificity to rapamycin. With such similar cellular
concentrations of binding proteins, and nearly identical pharmacokinetic and
physicochemical properties[20], Rapamycin-eluting stents will likely behave very
similarly to Paclitaxel in the setting of thrombus.
Drug Uptake and Stent Positioning
Our simulations demonstrate intriguing relationships between stent positioning
and arterial Paclitaxel uptake. The effects of positioning are primarily mediated by the
local transport forces which drive the migration of drug through the clot to the arterial
wall[7]. Macromolecular transport in thrombus has been a fertile area of research in
thrombolytic therapy, as researchers have sought ways to enhance clot uptake of
thrombolytic drugs and enzymes to maximize clot dissolution[ 16, 23, 24]. Controlling the
thrombus is a delicate issue in stent-based drug delivery as efforts to modulate uptake
must be balanced with concern for creating local zones of toxic or sub-therapeutic drug
levels[7]. In general, arterial drug uptake is decreased for clot configurations with larger
luminal surface area, stent positioning which increase the strut-to-intima distance and for
narrow clots which allow for a steep stent-lumen concentration gradient that washes drug
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out to the circulation. In some instances, even changes in stent positioning of just tens of
microns have dramatic effects in raising or lowering arterial drug uptake. Deploying a
stent in a pre-existing thrombus or thrombus that develops after implantation are both
cases where these effects may be realized.
Conclusions
Clots can modulate stent-based drug elution to alter significantly arterial drug
levels and potentially efficacy. Thrombus composition influences uptake kinetics through
changes in its retention capacity for drug. Clot geometry mediates arterial drug levels
through the balance of local transport forces. The exquisite sensitivity of tissue uptake to
geometry and composition implies that drug deposition will be highly variable and
difficult to predict in a thrombotic micro-environment. As such, the full power of drug-
eluting stents in clinical practice may not be entirely realized until local thrombosis is
tightly controlled.
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APPENDIX A
Simulation Code
% 2D Thrombus Transport Program 1.0, v 505n
% 1. Stent release 1 unit of drug per 100* 100 um^2 per sec
% 2. Partitioning referenced to Lumen only.
/% NEUMANN STENT RELEASE CONDITION
clear all; close all;
v ='505n'; % Version #
disp(['2D Thrombus Transport 1.0, v 'v ': NEUMANN RELEASE']);
disp(['Last modified by Chao-Wei Hwang']);
% TRANSPORT CONSTANTS -----------------
% Constants in um's and sec's (or HRS where indicated)
umV = 0.01;
umDTisX = 37.2;
umDTisY = 0.073;
umDClot = 250;
umDLumn = 250;
KLumnLumn = 1;
KClotLumn = 1;
KTissLumn --:= 30;
KTissClot = KTissLumn/KClotLumn; % All K will be represented relative to lumen (1) -
-> assume linear K relationship;
STENTRELEASERATE = 1; % units/100*100 umA2/sec
totalhrs = 1000;
% GEOMETRY CONSTANTS -----------------------
CLOTWIDTH = 300; % microns
CLOTHEIGHT = 300; % microns
STENTDIST = 0; % stent distance from intima in microns
STENTWIDTH = 100; % microns
STENTHEIGHT = 100; % microns
TISSUEWIDTH = 1000; % microns
TISSUEHEIGHT = 800; % microns
LUMENHEIGHT = 500; % microns;
O/ % - - - - - - - - - - - - - - - - - - - - -
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% SCALING FACTORS ---------------------
% To ensure stability in FD, can either scale space or time, but not both.
pix2um = 50; % 1 pixel = 50 um
V' = umV/pix2um;
DTisX = umDTisX/pix2um/pix2um;
DTisY = um:DTisY/pix2um/pix2um;
DClot = umDClot/pix2um/pix2um;
DLumn = umDLumn/pix2um/pix2um;
dx = 1; % in pix
dt = dx^2/(2*max([DTisX DTisY DClot DLumn]))*0.99; % time in seconds
simulcycles ::= totalhrs*3600/dt;
% -------------------------------------
% LOCATION OF TISSUE, STENT, CLOT, LUMEN MATRICES -----------------
n = ceil((TISSUEHEIGHT+LUMENHEIGHT)/pix2um)+2; % Number of pixels in Y
direction necessary to simulate 1500 um (deep into artery)
m = ceil(TISSUEWIDTH/pix2um)+2; % Number of pixels in X direction
% Denote location of tissue, stent, clot, lumen by l's.
Tiss = zeros(m,n);
TissTop = n-ceil(TISSUEHEIGHT/pix2um);
Tiss(2:m-l,TissTop:n-1) = 1;
Stnt = zeros(m,n);
StntBot = TissTop-ceil(STENTDIST/pix2um)- 1;
StntTop = StntBot-ceil(STENTHEIGHT/pix2um)+1;
StntLft = floor((m/2)-(STENTWIDTH/2)/pix2um)+ 1;
StntRgt = floor((m/2)+(STENTWIDTH/2)/pix2um);
Stnt(StntLft:StntRgt,StntTop:StntBot) = 1;
Clot = zeros(m,n);
ClotBot = TissTop-l;
ClotTop = ClotBot-ceil(CLOTHEIGHT/pix2um)+l;
ClotLft = floor((m/2)-(CLOTWIDTH/2)/pix2um)+1;
ClotRgt = floor((m/2)+(CLOTWIDTH/2)/pix2um);
Clot(ClotLft:ClotRgt,ClotTop:ClotBot) = 1;
Clot = Clot-Stnt;
Lumn = zeros(m,n);
Lumn(2:m-1,2:n-1) = 1 - Tiss(2:m-1,2:n-1) - Clot(2:m-1,2:n-1) - Stnt(2:m-1,2:n-1);
0,.)
% INITIALIZE SIMULATION MATRICES ------
C = zeros(m,n); % Tissue concentration
U = zeros(m,n); % Working Bulk concentration
CF = zeros(m,n); % Free portion of tissue concentration
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NF = zeros(m,n); % Fraction of new drug concentration that should remain free after
transport
DX = DTisX*Tiss+DClot*Clot+DClot*Stnt+DLumn*Lumn;
DY = DTisY*Tiss+DClot*Clot+DClot*Stnt+DLumn*Lumn;
K = zeros(m,n) + Tiss*KTissLumn + Clot*KClotLumn + Stnt*KClotLumn +
Lumn*KLumnLumn;
0/ ------------..------------------------..
% COMPUTATIONAL MATRICES and VARIABLES
rD = dt/(2*dx^2); rV = dt*V/dx;
DX1=zeros(m,n); DX2=zeros(m,n); DX3=zeros(m,n); DY1=zeros(m,n);
DY2=zeros(m,n); DY3=zeros(m,n);
ChangeXandY=zeros(m,n); ChangeV=zeros(m,n);
DX1(2:m-1,2:n-1) = DX(1 :m-2,2:n-l)+DX(2:m-1,2:n-1);
DX2(2:m- 1,2:n- 1) = DX(1 :m-2,2:n- 1 )+2*DX(2:m- 1,2:n- 1 )+DX(3:m,2:n- 1);
DX3(2:m- 1,2:n- 1) = DX(2:m-1 ,2:n- 1 )+DX(3 :m,2:n- 1);
DY1(2:m-1,2:n-1) = DY(2:m-1,1 :n-2)+DY(2:m-1,2:n-1);
DY2(2:m-1,2:n-1) = DY(2:m-1,1 :n-2)+2*DY(2:m- 1,2:n- 1 )+DY(2:m-1,3:n);
DY3(2:m-1,2:n-1) = DY(2:m- 1,2:n-1)+DY(2:m-1,3:n);
displaypercent = 1; % Display every displaypercent% of completion
tic;
elapsedtime := 0;
% MAIN SIMULATION LOOP ----------------
% Works with free drug diffusion and convection only
% Release first batch of drug
StentReleaseMatrix = zeros(m,n);
StentReleaseMatrix(2 :m- 1,2:n- 1) = (Stnt(2:m- 1,2:n-
1)*STENTRELEASERATE/(100* 100/pix2um/pix2um)*dt);
for t = 1 :simulcycles
% STEP 1: Release drug, and impose boundary conditions
U = U + StentReleaseMatrix;
U(1,:)=U(2,:); U(m,:)=U(m-1,:);
% STEP 2: Compute diffusion and convection of free drug + newly released drug
ChangeXandY(2:m-1,2:n-1) = rD*(DX1(2:m-1,2:n-1).*U(1 :m-2,2:n-1) + DY1(2:m-
1,2:n-1).:2:).*U(2:m- 1, :n-2) -...
(DX2(2:m-1,2:n-l1)+DY2(2:m-1,2:n-1)).*U(2:m-1,2:n-1) + ...
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DX3(2:m-1 ,2:n- 1).*U(3 :m,2:n- 1) + DY3(2:m-1 ,2:n- 1).*U(2:m-1,3:n));
ChangeV(2:m- 1,2:n- 1) = rV*(U(2:m- 1,1 :n-2)-U(2:m- 1,2:n- 1));
U = (U+ChangeXandY+ChangeV) .* (1-Lumn);
% STEP 3: From the post-transport drug distribution, calculate fraction of
% newly released drug that should remain free (NF)
CF(2:m-1,2:n-1) = C(2:m-1,2:n-1) ./ K(2:m-1,2:n-1);
NF(2:m- 1,2:n-1) = (U(2:m-1,2:n-1)-CF(2:m-1,2:n-1)) ./ K(2:m-1,2:n-1);
% STEP 4: Calculate new tissue concentration
C(2:m-1,2:n-1) = C(2:m-1,2:n-1) + U(2:m-1,2:n-1) - CF(2:m-1,2:n-1);
% STEP 5: Calculate total amount of drug in remaining in bulk phase
U(2:m-1,2:n-1) = CF(2:m-1,2:n-1) + NF(2:m-1,2:n-1);
if (mod(t,round(displaypercent/1 00O*simulcycles)) == 0)
simtime = t*dt; % Actual simulation time in seconds
disp([' ']);
disp(['--> Simulating ' num2str(simtime/3600) 'hours, tissue drug ='
num2str(sum(sum(C.*Tiss)))]);
subplot( 1,2,1);
pcolor(2*Tiss(2:m- 1 ,2:n- 1 )+Lumn(2:m- 1,2:n- 1 )+3 *Clot(2:m- 1,2:n- 1 )+4*Stnt(2:m-
1,2:n-.1)), view(90,90), shading faceted, axis equal, axis tight, axis off;
title('Simulation configuration');
subplot( 1,2,2);
pcolor(C(2:m-1,2:n-1)), view(90,90), shading faceted, axis equal, axis tight, axis off;
title(['Time: ' num2str(round(simtime/3600)) ' hrs.']);
drawnow;
if(min(min(C)) < 0)
error( 'Numerical instability.');
% If C < 0, washout too quick due to discretization, so becomes negative?
% Can also make 0 all C < 0 by ==> C = (C >= 0) .* C;
end;
elapsedtime = elapsedtime + toc;
disp(['Computation time:' num2str(elapsedtime/60) ' mn, speed'
num2str(round((dt*t)/elapsedtime)) 'X, est ' num2str((simulcycles-
t)/(t/elapsedtime)/60) ' mn left.']);
tic;
end;
end;
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simtime = t*dt; % Actual simulation time in seconds
disp([' ']);
disp(['--> Simulating ' num2str(simtime/3600) 'hours, tissue drug ='
num2str(sum(sum(C.*Tiss)))]);
subplot(l,2,1);
pcolor(2*Tiss(2 :m- 1 ,2:n- 1 )+Lumn(2:m- 1,2:n- 1 )+3*Clot(2:m- 1,2:n- 1 )+4* Stnt(2:m- 1,2:n-
1)), view(90,90), shading faceted, axis equal, axis tight, axis off;
title('Simulation configuration');
subplot(1,2,2);
pcolor(C(2:m-l,2:n-1)), view(90,90), shading faceted, axis equal, axis tight, axis off;
title(['Time: ' num2str(round(simtime/3600)) ' hrs.']);
drawnow;
elapsedtime == elapsedtime + toc;
disp([' ']);
disp(['Total computation time: ' num2str(elapsedtime/60) ' mn, speed'
num2str(round((dt*t)/elapsedtime)) 'X, est ' num2str((simulcycles-
t)/(t/elapsedtime)/60) ' mn left.']);
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Chapter 5
Conclusion
Thesis Summary
After great trial and error the elution of specific drugs from endovascular stents
now appears to be the most effective long term therapy for obstructive coronary artery
disease. In a fascinating turn the rational selection of drugs on the basis of biological
activity failed. Powerful vasoactive agents such as heparin regulate each of the
individual events in the vascular response to stenting and fail to affect the ultimate
development of restenosis. It appears that the physico-chemical properties of the drugs
take far greater precedence. Hydrophilic compounds, like heparin, are rapidly cleared
from vascular tissue and are consequently therapeutically ineffective for DES.
Hydrophobic species with high tissue binding capacity enter and are cleared from tissue
much more slowly, increasing overall residence time. The two compounds currently
clinically approved for use have specific and general means of tissue binding. While
specific binding is a seemingly obvious attribute of these compounds the general binding
events may be equally important. Rapamycin's interaction with the FKBP protein and
paclitaxel's association with polymerized microtubules are responsible for their
biological activity. But, the general binding of these drugs to other tissue elements also
plays a major role in determining the prolonged tissue retention and overall
pharmacokinetics. Physiochemical specific and general binding has emerged as one of
the fundamental mechanisms contributing to the success of DES, and must be a
consideration in the rational design of local delivery devices.
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5.1 Specific Findings
This thesis consists of a series of experiments designed to explore the roles of
specific and general binding in local arterial drug delivery.
In chapter 2, we defined the pharmacokinetic implications of specific binding to
arterial drug transport. Characteristics of hydrophobic, and clinically relevant, rapamycin
and paclitaxel were compared with the model hydrophilic compound, dextran. We found
that hydrophobic compounds enter and elute out of arterial tissues much more slowly
than hydrophilic ones. Hydrophobic diffusion coefficients are two log orders slower than
hydrophilic compounds like dextran and, diffusivity of all drugs in the planar direction
exceeds that of the transmural direction by two to three orders of magnitude. Further,
paclitaxel and rapamycin maintain tissue concentrations 30-40 times that of dextran, with
specific binding to biologically relevant protein targets accounting for 35% and 50% of
binding for paclitaxel and rapamycin, respectively. Finally we discovered that paclitaxel
and rapamycin distribute transmurally in arterial tissue with starkly different profiles.
In chapter 3, we investigated the roles of specific and general binding by defining
the contribution of each in arterial transport and distribution. Using specific and general
blocking agents we found that both types of displacement can decrease tissue binding
capacity by near 50%. We saw that specific binding has higher contributions in the
media where target protein density is greater. Similarly, general binding contributions
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localized preferentially to the adventitia. We also focused on the question of paclitaxel's
and rapamycin's abilities to displace one another from specific and general binding sites.
Molecular and tissue assays confirmed that each drug does not displace the other from
specific binding sites but can perturb general binding at three log order concentration
excess. Such concentrations gradients may be relevant for competition scenarios of
systemically delivered compounds over local therapeutics. A screen of several
commonly administered cardiac drugs found a heterogeneity in general binding
competition characteristics.
In chapter 4, we applied our knowledge of specific and general binding properties
to the clinically important problem of stent deployment in a thrombotic environment.
After measuring a series of binding capacity, diffusion and convection parameters in
fibrin, red blood cells and whole blood we developed a finite difference model which
allowed us to study tissue uptake of drug for various stent and thrombus geometries. The
results showed that thrombus can act as both a protective cap to increase drug uptake or a
vehicle to enhance elution from the stent strut to the vessel lumen. Thrombus
composition influences uptake kinetics through changes in its retention capacity for drug
while clot geometry mediates arterial drug levels through the balance of local transport
forces. The exquisite sensitivity of tissue uptake to thrombus geometry and composition
implies that drug deposition will be highly variable and difficult to predict in a
thrombotic micro-environment.
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This thesis has identified and characterized several vital mechanistic factors
which derive the functionality of local drug delivery devices. While this work has
focused on arterial drug systems, the fundamental tenants are generalizable to many
delivery systems where specific and general binding will determine efficacy. We hope
that comprehension and application of these important factors will help optimize local
drug delivery therapeutics.
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5.2 Future Directions
Binding and Transport in Pathological Arteries
Vascular disease can significantly increase the complexity of arterial drug
transport and distribution, and possibly the binding site availability and distribution.
While animal models of neointimal, lipid-laden and stent-induced pathologies have long
existed[1, 2], the resulting lesions are highly variable and as a result, drug transport
studies in these lesions has remained difficult to assess experimentally. Nevertheless, our
studies of native arteries have defined general transport and binding baseline properties
for future comparisons to disease models. It has already been observed that a
hyperplastic neointimal layer has little, if any, distinct geometric orientation[3] while
containing high concentrations of microtubules and FKBP. Since the diffusive
anisotropy in the arterial wall is a product of the geometric orientation of smooth muscle
cells, the regular layering of tissues of differing permeabilities and binding site
availability, the new intima may yield isotropic transport behavior. Compared to the
hyperplastic neointima, lipid-laden atherosclerotic plaques might be expected to offer
increased general binding capacity for more highly hydrophobic drugs. Site-specific
pathology offers another opportunity for investigations; vascular branching points prove
technically difficult to stent and show reduced responsiveness to DES therapy. Finally,
stented arteries with highly compressed media may actually exhibit even higher diffusive
anisotropy than native arteries since medial compression tightly packs arterial tissue
layers together[4], further limiting transmural transport compared to planar transport. As
diseased arteries are the ultimate target of vascular drug delivery, the impact of
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pathological arterial states on tissue structure and drug binding and transport clearly
merits further experimental study.
Diabetes
While DES has made significant advances in the treatment of coronary artery
disease, the problem is far from solved. Restenosis still persists in some patients,
especially those with diabetes, for yet unexplained reasons. In some studies, using DES
in diabetic patients shows little benefit over bare metal stents. It is not yet clear whether
diabetic resistance to drug-eluting stent therapy is a result of alterations in binding site
availability, transport or signaling mechanisms. A major challenge in studying vascular
disease and diabetes is the lack of a good animal model. Rat vasculature does not
respond to injury in the same manner has human tissue. Pig diabetic models more
accurately recapitulate atherosclerotic pathology but inducing the model in these animals
is very expensive and requires extremely talented husbandry. Nonetheless, with type II
diabetes on the rise in most of the western world, mastery of the limitations in treating
this population is a must.
Cocktails
Despite, or perhaps because of, the clear complexity underlying human
physiology, the medical community is often cautious to embrace combination therapies.
The HIV triple cocktail is now a well accepted therapy. Regiments for treating heart
disease come in combinations beyond triples addressing hypertension, cholesterol,
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platelet activity, etc. Local stent delivery offers a unique opportunity to explore
combination therapies while limiting the complicated nature of evaluating secondary
systemic effects. Rapamycin and paclitaxel act through two entirely unique mechanism
to inhibit smooth growth and would likely be a more efficacious combination than either
drug alone.
More Vessels
As DES stent treatment move to other vessels such as the renal and carotid
arteries a number of important considerations arise. As discussed previously, the
composition of the target tissue will change the diffusive, convective and binding
properties of the eluted drug. For example, the carotid arteries are relatively large bore
with high elastin contents. Additionally, luminal washout may take on increased
importance when stenting non-coronary vessels. Stenting in the coronaries has the
distinct advantage of rapid systemic dilution of washed out drug. Stenting immediately
proximal to the kidneys or the brain may increase the toxic sensitivity of these organs.
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5.3 Generalizing the Lessons of Local Arterial Transport
Deliverv
Drug distribution within tissue is a function of the interplay between local
physiological transport forces and the physical characteristics of the target tissue[5, 6].
This statement is generalizable to any local drug delivery system but will be summarized
here in terms of local arterial drug delivery. The potential of local drug delivery is
tremendous once adequate targeting is achieved, and thus, a rational approach to the
design of local delivery devices requires careful consideration of the interplay of drug
with arterial tissue organization and composition, as well as factors that influence the
devices ability to interact with target tissue.
Basic Transport Principles
Local drug distribution is influenced by ultrastructure both through the geometric
organization and through the variable avidity for drug uptake of the component arterial
tissues. Drugs generally do not distribute evenly throughout blood vessels. Drug
transport is highly dependent upon direction and plane of the tissue, and their deposition
and uptake are determined by tissue binding. Animal studies have confirmed that drug
delivery performed in one arterial bed cannot be directly applied to other arterial beds
without factoring in the underlying variations in tissue composition and organization.
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Specific and General Binding
While we have previously observed that dextrans and heparin naturally sequester
into specific connective tissue layers within the arterial wall[7, 8], hydrophobic
compounds like rapamycin and paclitaxel bind tightly to their target proteins in addition
to general associations. These binding interactions determine diffusive, distributive and
tissue residence time properties which dominant the efficacy of these treatments.
Microenvironment and DES
Variation in the local microenvironment immediately adjacent to the delivery
device can significantly impact device performance. Clots immediately adjacent to stent
struts can modulate the DES properties to significantly alter arterial drug levels and
potentially efficacy of treatment. Thrombus composition influences uptake kinetics
through changes in its retention capacity for drug while clot geometry mediates arterial
drug levels through the balance of local transport forces. The exquisite sensitivity of
tissue uptake to thrombus geometry and composition implies that drug deposition will be
highly variable and difficult to predict in a thrombotic micro-environment.
Rational Local Delivery Design
Incorporation of all these concepts into local drug delivery design is essential to
developing successful therapeutics. While no simple formula exists to integrate the
multifaceted considerations, care must be taken to evaluate each parameter to achieve
optimal delivery.
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